ETS1	B-protein
,	O
NFkappaB	B-protein
and	O
AP1	B-protein
synergistically	O
transactivate	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O

Activation	O
of	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	B-protein
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
is	O
one	O
such	O
cytokine	B-protein
,	O
whose	O
increased	O
expression	O
results	O
mostly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis-acting	B-DNA
elements	I-DNA
with	O
NFkappaB	B-DNA
,	I-DNA
AP1	I-DNA
and	I-DNA
ETS-like	I-DNA
binding	I-DNA
motifs	I-DNA
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
,	O
and	O
are	O
important	O
or	O
essential	O
for	O
transcriptional	O
activity	O
following	O
T	O
cell	O
activation	O
.	O

ETS1	B-protein
is	O
a	O
transcription	B-protein
factor	I-protein
of	O
the	O
ETS	B-protein
family	I-protein
that	O
is	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
have	O
previously	O
shown	O
that	O
ETS1	B-protein
can	O
transactivate	O
GM-CSF	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O

Thus	O
we	O
proposed	O
that	O
ETS1	B-protein
,	O
which	O
is	O
expressed	O
constitutively	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
may	O
act	O
in	O
concert	O
with	O
PMA/ionomycin	B-protein
inducible	I-protein
factors	I-protein
.	O

Here	O
we	O
show	O
that	O
ETS1	B-protein
can	O
transactivate	O
a	O
GM-CSF	B-DNA
reporter	I-DNA
construct	I-DNA
in	O
unstimulated	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
providing	O
that	O
either	O
NFkappaB	B-protein
or	O
AP1	B-protein
transcription	B-protein
factors	I-protein
are	O
supplied	O
by	O
co-transfection	O
.	O

We	O
confirm	O
that	O
binding	O
of	O
endogenous	O
NFkappaB	B-protein
and	O
AP1	B-protein
is	O
induced	O
following	O
PMA/ionomycin	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

Transactivation	O
by	O
ETS1	B-protein
,	O
NFkappaB	B-protein
and	O
AP1	B-protein
is	O
synergistic	O
,	O
and	O
mutation	O
of	O
the	O
individual	O
binding	O
sites	O
reveals	O
that	O
the	O
transcriptional	O
activities	O
of	O
these	O
factors	O
are	O
interdependent	O
.	O

Our	O
results	O
suggest	O
that	O
constitutive	O
ETS1	B-protein
,	O
and	O
inducible	O
NFkappaB	B-protein
and	O
AP1	B-protein
,	O
cooperate	O
as	O
part	O
of	O
a	O
higher	O
order	O
transcriptional	B-protein
complex	I-protein
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

Oncogene	NULL
(	NULL
1997	NULL
)	NULL
14	NULL
,	NULL
2845-2855	NULL
Â©	NULL
1997	NULL
Stockton	NULL
Press	NULL
All	NULL
rights	NULL
reserved	NULL
0950-9232/97	NULL
$	NULL
12.00	NULL
ETS1	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
synergistically	NULL
transactivate	NULL
the	NULL
human	NULL
GM-CSF	NULL
promoter	NULL
Ross	NULL
S	NULL
Thomas	NULL
!	NULL

,	NULL
Martin	NULL
J	NULL
Tymms	NULL
'	NULL
,	NULL
Leigh	NULL
H	NULL
McKinlay	NULL
'	NULL
,	NULL
M	NULL
Frances	NULL
Shannon	NULL
,	NULL
Arun	NULL
Seth	NULL
and	NULL
Ismarl	NULL
Kola	NULL
!	NULL

'Molecular	NULL
Genetics	NULL
and	NULL
Development	NULL
Group	NULL
,	NULL
Institute	NULL
of	NULL
Reproduction	NULL
and	NULL
Development	NULL
,	NULL
Monash	NULL
University	NULL
,	NULL
Melbourne	NULL
3168	NULL
,	NULL
Australia	NULL
;	NULL
``	NULL
Division	NULL
of	NULL
Human	NULL
Immunology	NULL
,	NULL
Hanson	NULL
Centre	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
Institute	NULL
of	NULL
Medical	NULL
and	NULL
Veterinary	NULL
Science	NULL
,	NULL
Adelaide	NULL
5000	NULL
,	NULL
Australia	NULL
;	NULL
'Department	NULL
of	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Toronto|	NULL
Women	NULL
's	NULL
College	NULL
Hospital	NULL
,	NULL
Toronto	NULL
,	NULL
Ontario	NULL
,	NULL
Canada	NULL
Activation	NULL
of	NULL
helper	NULL
T	NULL
cells	NULL
results	NULL
in	NULL
coordinate	NULL
expression	NULL
of	NULL
a	NULL
number	NULL
of	NULL
cytokines	NULL
involved	NULL
in	NULL
differentiation	NULL
,	NULL
proliferation	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
haematopoietic	NULL
system	NULL
.	NULL

Granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
is	NULL
one	NULL
such	NULL
cytokine	NULL
,	NULL
whose	NULL
increased	NULL
expression	NULL
results	NULL
mostly	NULL
from	NULL
increases	NULL
in	NULL
transcription	NULL
.	NULL

Cis-acting	NULL
elements	NULL
with	NULL
NFxB	NULL
,	NULL
API	NULL
and	NULL
ETS-like	NULL
binding	NULL
motifs	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
,	NULL
and	NULL
are	NULL
important	NULL
or	NULL
essential	NULL
for	NULL
transcriptional	NULL
activity	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

ETS1	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
of	NULL
the	NULL
ETS	NULL
family	NULL
that	NULL
is	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
ETS1	NULL
can	NULL
transactivate	NULL
GM-CSF	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
only	NULL
after	NULL
the	NULL
cells	NULL
have	NULL
been	NULL
stimulated	NULL
by	NULL
treatment	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
agents	NULL
that	NULL
mimic	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Thus	NULL
we	NULL
proposed	NULL
that	NULL
ETS1	NULL
,	NULL
which	NULL
is	NULL
expressed	NULL
constitutively	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
may	NULL
act	NULL
in	NULL
concert	NULL
with	NULL
PMA	NULL
ionomycin	NULL
inducible	NULL
factors	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
ETS1	NULL
can	NULL
transactivate	NULL
a	NULL
GM-CSF	NULL
reporter	NULL
construct	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
providing	NULL
that	NULL
either	NULL
NFxB	NULL
or	NULL
API	NULL
transcription	NULL
factors	NULL
are	NULL
supplied	NULL
by	NULL
co-transfection	NULL
.	NULL

We	NULL
confirm	NULL
that	NULL
binding	NULL
of	NULL
endogenous	NULL
NFxB	NULL
and	NULL
API	NULL
is	NULL
induced	NULL
following	NULL
PMA/ionomycin	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Transactivation	NULL
by	NULL
ETS1	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
is	NULL
synergistic	NULL
,	NULL
and	NULL
mutation	NULL
of	NULL
the	NULL
individual	NULL
binding	NULL
sites	NULL
reveals	NULL
that	NULL
the	NULL
transcriptional	NULL
activities	NULL
of	NULL
these	NULL
factors	NULL
are	NULL
inter-dependent	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
constitutive	NULL
ETS1	NULL
,	NULL
and	NULL
inducible	NULL
NFxB	NULL
and	NULL
API	NULL
,	NULL
cooperate	NULL
as	NULL
part	NULL
of	NULL
a	NULL
higher	NULL
order	NULL
transcriptional	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Keywords	NULL
:	NULL
GM-CSF	NULL
;	NULL
Transcription	NULL
;	NULL
ETSl	NULL
;	NULL
NFkB	NULL
;	NULL
API	NULL
Introduction	NULL
Helper	NULL
T	NULL
cells	NULL
are	NULL
activated	NULL
,	NULL
and	NULL
initiate	NULL
an	NULL
immune	NULL
response	NULL
,	NULL
through	NULL
recognition	NULL
of	NULL
specific	NULL
antigens	NULL
presented	NULL
by	NULL
antigen	NULL
presenting	NULL
cells	NULL
.	NULL

Activation	NULL
is	NULL
primarily	NULL
mediated	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
,	NULL
which	NULL
enhances	NULL
intracellular	NULL
calcium	NULL
levels	NULL
and	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
activity	NULL
(	NULL
Miyajima	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Valge	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Klausner	NULL
and	NULL
Samelson	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

These	NULL
events	NULL
can	NULL
be	NULL
mimicked	NULL
in	NULL
culture	NULL
by	NULL
addition	NULL
of	NULL
the	NULL
calcium	NULL
ionophore	NULL
,	NULL
ionomycin	NULL
and	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
activator	NULL
,	NULL
PMA	NULL
(	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
)	NULL
.	NULL

Correspondence	NULL
:	NULL
I	NULL
Kola	NULL
Received	NULL
31	NULL
October	NULL
1996	NULL
;	NULL
revised	NULL
28	NULL
February	NULL
1997	NULL
;	NULL
accepted	NULL
28	NULL
February	NULL
1997	NULL
Activating	NULL
signals	NULL
ultimately	NULL
result	NULL
in	NULL
cellular	NULL
prolifera-tion	NULL
,	NULL
and	NULL
transcriptional	NULL
induction	NULL
and	NULL
secretion	NULL
of	NULL
a	NULL
number	NULL
of	NULL
cytokines	NULL
including	NULL
IL-2	NULL
(	NULL
interleukin-2	NULL
)	NULL
,	NULL
IL-3	NULL
,	NULL
IFNy	NULL
(	NULL
interferon-gamma	NULL
)	NULL
and	NULL
GM-CSF	NULL
(	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
)	NULL
(	NULL
Stanley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Miyajima	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

These	NULL
cytokines	NULL
direct	NULL
the	NULL
effector	NULL
functions	NULL
of	NULL
various	NULL
cell	NULL
types	NULL
involved	NULL
in	NULL
an	NULL
immune	NULL
response	NULL
,	NULL
including	NULL
B	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
mast	NULL
cells	NULL
,	NULL
eosinophils	NULL
and	NULL
neutrophils	NULL
.	NULL

GM-CSF	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
is	NULL
regulated	NULL
by	NULL
two	NULL
mechanisms	NULL
.	NULL

Firstly	NULL
,	NULL
GM-CSF	NULL
transcription	NULL
is	NULL
controlled	NULL
by	NULL
both	NULL
constitutive	NULL
and	NULL
inducible	NULL
transcription	NULL
factors	NULL
that	NULL
interact	NULL
with	NULL
the	NULL
proximal	NULL
promoter	NULL
(	NULL
Sugimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Koyano-Nakagawa	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
and	NULL
a	NULL
distal	NULL
enhancer	NULL
shared	NULL
by	NULL
GM-CSF	NULL
and	NULL
IL-3	NULL
(	NULL
Cockerill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Osborne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Secondly	NULL
,	NULL
GM-CSF	NULL
mRNA	NULL
stability	NULL
is	NULL
controlled	NULL
through	NULL
an	NULL
AU	NULL
rich	NULL
3	NULL
'	NULL
region	NULL
(	NULL
Shaw	NULL
and	NULL
Kamen	NULL
,	NULL
1986	NULL
;	NULL
Iwai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
although	NULL
the	NULL
importance	NULL
of	NULL
this	NULL
mechanism	NULL
has	NULL
been	NULL
questioned	NULL
(	NULL
Brorson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Essential	NULL
elements	NULL
in	NULL
the	NULL
proximal	NULL
promoter	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
include	NULL
the	NULL
CLE2	NULL
(	NULL
conserved	NULL
lymphokine	NULL
element	NULL
)	NULL
/GC-box	NULL
region	NULL
,	NULL
which	NULL
supports	NULL
the	NULL
binding	NULL
of	NULL
inducible	NULL
NFxB/Rel	NULL
and	NULL
constitutive	NULL
Spl	NULL
family	NULL
members	NULL
,	NULL
and	NULL
CLEO	NULL
,	NULL
which	NULL
binds	NULL
inducible	NULL
API	NULL
and	NULL
constitutive	NULL
ETS	NULL
factors	NULL
.	NULL

An	NULL
inducible	NULL
NFAT-like	NULL
complex	NULL
(	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
also	NULL
displays	NULL
weak	NULL
binding	NULL
to	NULL
CLEO	NULL
.	NULL

The	NULL
CLEO	NULL
region	NULL
has	NULL
been	NULL
described	NULL
as	NULL
a	NULL
part	NULL
of	NULL
a	NULL
triple	NULL
repeat	NULL
CATT	NULL
(	NULL
A/T	NULL
)	NULL
element	NULL
by	NULL
others	NULL
(	NULL
Nimer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
other	NULL
factors	NULL
have	NULL
recently	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
GM-CSF	NULL
transcriptional	NULL
control	NULL
.	NULL

CBF	NULL
(	NULL
Core	NULL
Binding	NULL
Factor	NULL
)	NULL
(	NULL
Takahashi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Cockerill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
and	NULL
YYI	NULL
(	NULL
Yin-Yang	NULL
1	NULL
)	NULL
(	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
,	NULL
1996	NULL
)	NULL
appear	NULL
to	NULL
exert	NULL
positive	NULL
and	NULL
negative	NULL
effects	NULL
,	NULL
respectively	NULL
,	NULL
upon	NULL
GM	NULL
CSF	NULL
transcription	NULL
.	NULL

These	NULL
two	NULL
factors	NULL
bind	NULL
a	NULL
region	NULL
between	NULL
the	NULL
CLE2	NULL
and	NULL
CLEO	NULL
elements	NULL
.	NULL

Previously	NULL
we	NULL
have	NULL
characterised	NULL
the	NULL
binding	NULL
of	NULL
ETSl	NULL
and	NULL
other	NULL
ETS	NULL
family	NULL
members	NULL
,	NULL
to	NULL
the	NULL
ETS	NULL
binding	NULL
site	NULL
within	NULL
the	NULL
CLEO	NULL
element	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Our	NULL
experiments	NULL
suggested	NULL
that	NULL
ETS1l	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
GM-CSF	NULL
transcription	NULL
following	NULL
PMA	NULL
and	NULL
ionomycin	NULL
stimulation	NULL
,	NULL
and	NULL
hence	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
we	NULL
found	NULL
that	NULL
ETS1l	NULL
binding	NULL
appeared	NULL
to	NULL
be	NULL
constitutive	NULL
,	NULL
and	NULL
that	NULL
ETS1	NULL
could	NULL
not	NULL
transactivate	NULL
GM-CSF	NULL
unless	NULL
the	NULL
T	NULL
cells	NULL
were	NULL
first	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
:	NULL
(	NULL
1	NULL
)	NULL
ETSl	NULL
does	NULL
not	NULL
instigate	NULL
GM-CSF	NULL
transcription	NULL
and	NULL
;	NULL
(	NULL
2	NULL
)	NULL
either	NULL
ETSl	NULL
is	NULL
modified	NULL
by	NULL
PMA/ionomycin	NULL
treatment	NULL
or	NULL
other	NULL
factors	NULL
induced	NULL
by	NULL
PMA/ionomy-	NULL
Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
2846	NULL
``	NULL
600	NULL
600bp	NULL
Human	NULL
GM-CSF	NULL
Promoter	NULL
H	NULL
CAT	NULL
|	NULL
--	NULL
pGM600	NULL
CLE2	NULL
GC-box	NULL
CLEO	NULL
TATA	NULL
Â«	NULL
90	NULL
-80	NULL
-10	NULL
-60	NULL
-40	NULL
-30	NULL
-20	NULL
10	NULL
p	NULL
>	NULL
TfCAGST	NULL
ABT	NULL
TEJECCGCE	NULL
NCCC	NULL
TTETEGTCACGAT	NULL
TAATCATT	NULL
Tce	NULL
TG	NULL
GTGT	NULL
AGCTCTTTTGCCAGTGAGCCCACGTACA	NULL
Ab	NULL
recA	NULL
TCGAGAAAACGGTCACTCGGGTGCATET	NULL
-v-	NULL
-y	NULL
--	NULL
-	NULL
,	NULL
--	NULL
NFkB	NULL
Sp-1	NULL
CBEVY1	NULL
_	NULL
APA	NULL
ETS	NULL
AGAGGAAAT	NULL
.-	NULL
GMEts	NULL
AGAAGAMAT	NULL
.-	NULL
GMETSm	NULL
er	NULL
nnn	NULL
pGM600-ETSm1	NULL
-	NULL
ames	NULL
AGCGGAAGC	NULL
.-	NULL
MSV	NULL
(	NULL
ETS	NULL
consensus	NULL
)	NULL
@	NULL
ETTAACT	NULL
-	NULL
GMeBm	NULL
nnn	NULL
rev	NULL
pGM600-Bm1	NULL
GGGGACTT	NULL
.-	NULL
NFKB	NULL
consensus	NULL
Traitck	NULL
-	NULL
gmari	NULL
GATAGCA	NULL
|-	NULL
GMAPIm	NULL
sorce	NULL
pGM600-AP1m1	NULL
TGAGTCA	NULL
--	NULL
API	NULL
consensus	NULL
Figure	NULL
1	NULL
-	NULL
Structure	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
CAT	NULL
constructs	NULL
and	NULL
oligonucleotide	NULL
sequences	NULL
.	NULL

The	NULL
600	NULL
bp	NULL
human	NULL
GM-CSF	NULL
promoter	NULL
contains	NULL
a	NULL
transcriptional	NULL
control	NULL
region	NULL
of	NULL
approximately	NULL
100	NULL
bp	NULL
proximal	NULL
to	NULL
transcriptional	NULL
initiation	NULL
(	NULL
arrow	NULL
)	NULL
.	NULL

This	NULL
region	NULL
contains	NULL
elements	NULL
conserved	NULL
among	NULL
the	NULL
promoters	NULL
of	NULL
genes	NULL
expressed	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

The	NULL
CLE2	NULL
(	NULL
conserved	NULL
lymphokine	NULL
element	NULL
)	NULL
/GC-box	NULL
region	NULL
contains	NULL
binding	NULL
sites	NULL
for	NULL
the	NULL
NFxB	NULL
and	NULL
Spl	NULL
families	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

CLEO	NULL
contains	NULL
binding	NULL
sites	NULL
for	NULL
API	NULL
and	NULL
ETS	NULL
families	NULL
.	NULL

Other	NULL
elements	NULL
include	NULL
a	NULL
consensus	NULL
TATA	NULL
box	NULL
,	NULL
and	NULL
binding	NULL
regions	NULL
for	NULL
CBF	NULL
(	NULL
core	NULL
binding	NULL
factor	NULL
)	NULL
and	NULL
YY1	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
oligonucleotides	NULL
spanning	NULL
the	NULL
NFxB	NULL
,	NULL
API1	NULL
and	NULL
ETS	NULL
sites	NULL
and	NULL
their	NULL
mutations	NULL
are	NULL
shown	NULL
.	NULL

Consensus	NULL
binding	NULL
site	NULL
sequences	NULL
are	NULL
also	NULL
shown	NULL
.	NULL

pGM600	NULL
is	NULL
a	NULL
CAT	NULL
construct	NULL
driven	NULL
by	NULL
the	NULL
600	NULL
bp	NULL
wild-type	NULL
GM-CSF	NULL
promoter	NULL
.	NULL

Mutant	NULL
binding	NULL
sites	NULL
have	NULL
been	NULL
introduced	NULL
into	NULL
the	NULL
pGM600-ETS1	NULL
,	NULL
-xB	NULL
and	NULL
-AP1	NULL
constructs	NULL
,	NULL
as	NULL
indicated	NULL
cin	NULL
are	NULL
required	NULL
.	NULL

In	NULL
this	NULL
study	NULL
we	NULL
characterise	NULL
requirements	NULL
for	NULL
ETS1	NULL
transactivation	NULL
.	NULL

We	NULL
show	NULL
that	NULL
ETSl	NULL
can	NULL
transactivate	NULL
a	NULL
GM-CSF	NULL
reporter	NULL
construct	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
providing	NULL
that	NULL
either	NULL
or	NULL
both	NULL
NFxB	NULL
and	NULL
API	NULL
transcription	NULL
factors	NULL
are	NULL
supplied	NULL
exogenously	NULL
.	NULL

We	NULL
confirm	NULL
previous	NULL
studies	NULL
that	NULL
show	NULL
binding	NULL
of	NULL
endogenous	NULL
NFB	NULL
and	NULL
API	NULL
is	NULL
inducible	NULL
following	NULL
PMA/ionomycin	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Transactivation	NULL
by	NULL
ETS1l	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
is	NULL
synergistic	NULL
,	NULL
and	NULL
mutation	NULL
of	NULL
the	NULL
individual	NULL
binding	NULL
sites	NULL
reveals	NULL
that	NULL
the	NULL
transcriptional	NULL
activities	NULL
of	NULL
these	NULL
factors	NULL
are	NULL
inter-dependent	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
NFxB	NULL
and	NULL
API	NULL
may	NULL
be	NULL
additional	NULL
co-factors	NULL
required	NULL
for	NULL
ETSl	NULL
mediated	NULL
transactivation	NULL
,	NULL
and	NULL
that	NULL
these	NULL
three	NULL
factors	NULL
operate	NULL
synergistically	NULL
as	NULL
part	NULL
of	NULL
a	NULL
higher	NULL
order	NULL
transcriptional	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Results	NULL
ETSI	NULL
transactivation	NULL
requires	NULL
PMA	NULL
and	NULL
ionomycin	NULL
stimulation	NULL
or	NULL
additional	NULL
NFB	NULL
and/or	NULL
API	NULL
factors	NULL
A	NULL
CAT	NULL
reporter	NULL
construct	NULL
containing	NULL
600	NULL
bp	NULL
of	NULL
the	NULL
human	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
pGM600	NULL
)	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
was	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
effects	NULL
of	NULL
co-transfected	NULL
expression	NULL
constructs	NULL
and	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
were	NULL
analysed	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
raw	NULL
CAT	NULL
data	NULL
for	NULL
pGM600	NULL
,	NULL
with	NULL
the	NULL
various	NULL
treatment/co-transfections	NULL
,	NULL
was	NULL
normalised	NULL
to	NULL
its	NULL
basal	NULL
expression	NULL
,	NULL
which	NULL
was	NULL
given	NULL
the	NULL
value	NULL
of	NULL
'one	NULL
'	NULL
.	NULL

The	NULL
mean	NULL
of	NULL
at	NULL
least	NULL
four	NULL
replicates	NULL
for	NULL
each	NULL
experiment	NULL
was	NULL
graphed	NULL
to	NULL
show	NULL
a	NULL
'fold	NULL
induction	NULL
over	NULL
basal	NULL
pGM600	NULL
expression	NULL
,	NULL
to	NULL
facilitate	NULL
comparison	NULL
between	NULL
the	NULL
different	NULL
treatments/co-transfections	NULL
.	NULL

Co-transfection	NULL
of	NULL
an	NULL
ETSl	NULL
expression	NULL
construct	NULL
resulted	NULL
in	NULL
fourfold	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
reporter	NULL
,	NULL
but	NULL
only	NULL
if	NULL
the	NULL
cells	NULL
were	NULL
first	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Potentially	NULL
,	NULL
PMA/ionomycin	NULL
either	NULL
modifies	NULL
the	NULL
ETS1	NULL
protein	NULL
or	NULL
supplies	NULL
co-factors	NULL
required	NULL
for	NULL
ETS1l	NULL
transactivation	NULL
.	NULL

Because	NULL
the	NULL
GM	NULL
CSF	NULL
promoter	NULL
contains	NULL
binding	NULL
sites	NULL
for	NULL
other	NULL
transcription	NULL
factors	NULL
in	NULL
close	NULL
proximity	NULL
to	NULL
that	NULL
of	NULL
ETSl	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
transcriptional	NULL
interactivity	NULL
between	NULL
ETSl	NULL
,	NULL
NFxB	NULL
and	NULL
API1	NULL
factors	NULL
.	NULL

Transfection	NULL
of	NULL
NFxB	NULL
(	NULL
p50	NULL
and	NULL
p65	NULL
)	NULL
and	NULL
API	NULL
(	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
)	NULL
resulted	NULL
in	NULL
18-	NULL
and	NULL
ninefold	NULL
transactivation	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Figure	NULL
2	NULL
,	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Although	NULL
ETS1l	NULL
alone	NULL
could	NULL
not	NULL
produce	NULL
transactivation	NULL
in	NULL
unstimulated	NULL
cells	NULL
,	NULL
co-transfection	NULL
of	NULL
ETSl	NULL
with	NULL
NFxB	NULL
or	NULL
API	NULL
resulted	NULL
in	NULL
strong	NULL
synergistic	NULL
transactivation	NULL
.	NULL

ETS1	NULL
and	NULL
NFxB	NULL
together	NULL
resulted	NULL
in	NULL
increased	NULL
GM-CSF	NULL
transcription	NULL
123-fold	NULL
higher	NULL
than	NULL
basal	NULL
expression	NULL
-	NULL
sevenfold	NULL
higher	NULL
than	NULL
NFB	NULL
alone	NULL
.	NULL

ETSl	NULL
and	NULL
API	NULL
resulted	NULL
in	NULL
a	NULL
34-fold	NULL
increase	NULL
,	NULL
which	NULL
was	NULL
fourfold	NULL
higher	NULL
than	NULL
API	NULL
alone	NULL
.	NULL

NFxB	NULL
and	NULL
API	NULL
together	NULL
were	NULL
also	NULL
strongly	NULL
synergistic	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
308-fold	NULL
increase	NULL
in	NULL
transcription	NULL
compared	NULL
with	NULL
basal	NULL
expression	NULL
.	NULL

Maximal	NULL
synergistic	NULL
transactivation	NULL
was	NULL
achieved	NULL
with	NULL
all	NULL
three	NULL
transcription	NULL
factors	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
820-fold	NULL
increase	NULL
over	NULL
basal	NULL
expression	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
addition	NULL
of	NULL
ETSl	NULL
resulted	NULL
in	NULL
a	NULL
2.5-fold	NULL
increase	NULL
compared	NULL
to	NULL
just	NULL
NFxB/API	NULL
.	NULL

Thus	NULL
,	NULL
transactivation	NULL
by	NULL
ETS1	NULL
was	NULL
possible	NULL
in	NULL
PMA/ionomycin	NULL
treated	NULL
cells	NULL
or	NULL
in	NULL
unstimulated	NULL
cells	NULL
supplemented	NULL
with	NULL
exogenous	NULL
NFxB	NULL
and/or	NULL
API	NULL
transcription	NULL
factors	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
may	NULL
be	NULL
PMA	NULL
/ionomycin	NULL
induced	NULL
co-factors	NULL
required	NULL
for	NULL
ETSI	NULL
function	NULL
.	NULL

Consequently	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
whether	NULL
DNA	NULL
binding	NULL
to	NULL
ETS	NULL
,	NULL
NFB	NULL
and	NULL
API	NULL
sites	NULL
in	NULL
the	NULL
proximal	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
is	NULL
increased	NULL
upon	NULL
stimulation	NULL
of	NULL
Jurkat	NULL
cells	NULL
In	NULL
addition	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
identify	NULL
the	NULL
NFxB	NULL
and	NULL
API	NULL
factors	NULL
which	NULL
may	NULL
synergise	NULL
with	NULL
ETS1l	NULL
in	NULL
vivo	NULL
.	NULL

ETSI	NULL
binds	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
constitutively	NULL
EMSA	NULL
(	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
)	NULL
analysis	NULL
showed	NULL
that	NULL
a	NULL
number	NULL
of	NULL
proteins	NULL
in	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
bound	NULL
to	NULL
the	NULL
GMETS	NULL
sequence	NULL
contained	NULL
within	NULL
CLEO	NULL
,	NULL
-35	NULL
to	NULL
-44	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
Figure	NULL
3	NULL
-	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
labeled	NULL
n/s	NULL
appeared	NULL
to	NULL
represent	NULL
a	NULL
non-specific	NULL
DNA	NULL
binding	NULL
protein	NULL
capable	NULL
of	NULL
binding	NULL
any	NULL
oligonucleotide	NULL
sequence	NULL
.	NULL

The	NULL
complexes	NULL
A	NULL
,	NULL
B	NULL
and	NULL
C	NULL
were	NULL
competed	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
a	NULL
consensus	NULL
ETS	NULL
binding	NULL
site	NULL
(	NULL
MSV	NULL
)	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
by	NULL
GMETS	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

A	NULL
mutant	NULL
GMETS	NULL
sequence	NULL
(	NULL
GMETSm1l	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
core	NULL
of	NULL
the	NULL
ETS	NULL
binding	NULL
site	NULL
,	NULL
was	NULL
unable	NULL
to	NULL
compete	NULL
for	NULL
binding	NULL
of	NULL
these	NULL
complexes	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
and	NULL
did	NULL
not	NULL
display	NULL
binding	NULL
to	NULL
them	NULL
when	NULL
labeled	NULL
and	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
all	NULL
complexes	NULL
display	NULL
characteristics	NULL
consistent	NULL
with	NULL
DNA	NULL
binding	NULL
proteins	NULL
of	NULL
the	NULL
ETS	NULL
family	NULL
.	NULL

Complex	NULL
C	NULL
was	NULL
identified	NULL
as	NULL
ETS1l	NULL
by	NULL
its	NULL
specific	NULL
removal	NULL
with	NULL
addition	NULL
of	NULL
an	NULL
ETS1	NULL
antibody	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
and	NULL
the	NULL
just	NULL
visible	NULL
appearance	NULL
of	NULL
a	NULL
supershift	NULL
(	NULL
identified	NULL
by	NULL
the	NULL
open	NULL
arrow	NULL
)	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
complexes	NULL
A	NULL
and	NULL
B	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
determined	NULL
,	NULL
but	NULL
could	NULL
represent	NULL
binding	NULL
of	NULL
other	NULL
ETS	NULL
family	NULL
members	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
such	NULL
as	NULL
ETS2	NULL
,	NULL
GABP	NULL
Â«	NULL
and/or	NULL
FLIl	NULL
.	NULL

Binding	NULL
of	NULL
another	NULL
complex	NULL
,	NULL
above	NULL
that	NULL
of	NULL
complex	NULL
A	NULL
,	NULL
was	NULL
also	NULL
faintly	NULL
visible	NULL
(	NULL
small	NULL
arrow	NULL
)	NULL
.	NULL

Previously	NULL
we	NULL
have	NULL
identified	NULL
this	NULL
complex	NULL
as	NULL
Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
Fold	NULL
Treatment	NULL
!	NULL

Relative	NULL
CAT	NULL
Activity	NULL
(	NULL
Fold	NULL
Induction	NULL
)	NULL
Tranfection	NULL
aa	NULL
aa	NULL
to	NULL
~-	NULL
o	NULL
-	NULL
w	NULL
on	NULL
o	NULL
n	NULL
Â®	NULL
&	NULL
G	NULL
@	NULL
@	NULL
9	NULL
2	NULL
hrd	NULL
2	NULL
y	NULL
2	NULL
@	NULL
0	NULL
i	NULL
P329	NULL
29	NULL
R	NULL
XR	NULL
1.0	NULL
=	NULL
=	NULL
=	NULL
~	NULL
0.8	NULL
--	NULL
ETS1	NULL
-	NULL
4.9	NULL
PH	NULL
-	NULL
Do	NULL
.	NULL

RM	NULL
pousoo	NULL
=	NULL
-frke	NULL
]	NULL
15	NULL
P+	NULL
ETS	NULL
-	NULL
18	NULL
-	NULL
-	NULL
-	NULL
NFB	NULL
123	NULL
--	NULL
ETS1	NULL
NFB	NULL
8.8	NULL
=	NULL
-	NULL
-_	NULL
AP1	NULL
34	NULL
--	NULL
ETS1	NULL
-	NULL
AP1	NULL
308	NULL
-	NULL
-	NULL
NFB	NULL
API	NULL
Kei	NULL
--	NULL
-820	NULL
-	NULL
-	NULL
ETS1	NULL
NF	NULL
Â«	NULL
B	NULL
AP	NULL
~	NULL
--	NULL
Figure	NULL
2	NULL
CAT	NULL
analysis	NULL
of	NULL
pGM600	NULL
transactivation	NULL
by	NULL
ETSI	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
transcription	NULL
factors	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
pGM600	NULL
CAT	NULL
construct	NULL
is	NULL
shown	NULL
schematically	NULL
(	NULL
inset	NULL
)	NULL
.	NULL

Relative	NULL
CAT	NULL
activities/fold	NULL
induction	NULL
were	NULL
calculated	NULL
from	NULL
raw	NULL
CAT	NULL
data	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

Experiments	NULL
involve	NULL
combinations	NULL
of	NULL
PMA/ionomycin	NULL
(	NULL
P	NULL
+1	NULL
)	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
and	NULL
co-transfection	NULL
of	NULL
expression	NULL
vector	NULL
constructs	NULL
,	NULL
ETSI	NULL
,	NULL
NFxB	NULL
(	NULL
p50/p635	NULL
)	NULL
and	NULL
API	NULL
(	NULL
c-Fos/c-Jun	NULL
)	NULL
.	NULL

Experiments	NULL
without	NULL
particular	NULL
expression	NULL
vectors	NULL
were	NULL
transfected	NULL
instead	NULL
with	NULL
the	NULL
equivalent	NULL
amount	NULL
of	NULL
control	NULL
plasmids	NULL
(	NULL
pCMV	NULL
and/or	NULL
pEFBOS	NULL
)	NULL
PROBE	NULL
GMETS	NULL
m	NULL
1	NULL
Jur	NULL
-	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
PROTEIN	NULL
_	NULL
-_	NULL
P+l	NULL
_	NULL
P+l_	NULL
Pel	NULL
Perl	NULL
P+el	NULL
P+	NULL
ANTIBODY/	NULL
comPETiTor	NULL
~	NULL
-	NULL
_	NULL
MSV	NULL
GMETS	NULL
m1	NULL
aBts1	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
a	NULL
<	NULL
=	NULL
comp	NULL
A	NULL
-	NULL
Â®	NULL
n/s	NULL
&	NULL
t	NULL
!	NULL

$	NULL
4	NULL
**	NULL
comp	NULL
B	NULL
comp	NULL
C	NULL
(	NULL
ETS1	NULL
)	NULL
Figure	NULL
3	NULL
EMSA	NULL
analysis	NULL
of	NULL
the	NULL
ETS	NULL
factors	NULL
able	NULL
to	NULL
bind	NULL
the	NULL
GMETS	NULL
sequence	NULL
in	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
.	NULL

The	NULL
labeled	NULL
oligonucleotide	NULL
(	NULL
probe	NULL
)	NULL
is	NULL
either	NULL
GMETS	NULL
or	NULL
GMETSm1	NULL
(	NULL
also	NULL
referred	NULL
to	NULL
as	NULL
m1	NULL
)	NULL
.	NULL

Protein	NULL
samples	NULL
were	NULL
Jurkat	NULL
(	NULL
Jur	NULL
)	NULL
cell	NULL
nuclear	NULL
lysates	NULL
,	NULL
either	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
PMA/ionomycin	NULL
treated	NULL
(	NULL
P+1	NULL
)	NULL
.	NULL

Antibodies	NULL
or	NULL
competitor	NULL
oligonucleotides	NULL
were	NULL
added	NULL
to	NULL
binding	NULL
reactions	NULL
as	NULL
indicated	NULL
.	NULL

Â«	NULL
Ets1	NULL
(	NULL
E44	NULL
)	NULL
is	NULL
an	NULL
ETS1	NULL
specific	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Three	NULL
ETS-like	NULL
factors	NULL
able	NULL
to	NULL
bind	NULL
GMETS	NULL
are	NULL
labeled	NULL
complex	NULL
(	NULL
comp	NULL
)	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C.	NULL
n/s	NULL
indicates	NULL
non-specific	NULL
binding	NULL
.	NULL

An	NULL
open	NULL
arrow	NULL
identifies	NULL
a	NULL
super-shifted	NULL
ETS1	NULL
complex	NULL
in	NULL
lane	NULL
6	NULL
.	NULL

A	NULL
small	NULL
arrow	NULL
indicates	NULL
ELFI1	NULL
binding	NULL
in	NULL
lane	NULL
2	NULL
ELF	NULL
]	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
but	NULL
can	NULL
not	NULL
consistently	NULL
detect	NULL
it	NULL
due	NULL
to	NULL
the	NULL
low	NULL
level	NULL
of	NULL
binding	NULL
.	NULL

The	NULL
ETS-like	NULL
complexes	NULL
(	NULL
A	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
displayed	NULL
strong	NULL
binding	NULL
to	NULL
the	NULL
GMETS	NULL
site	NULL
.	NULL

Nuclear	NULL
lysates	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
displayed	NULL
little	NULL
difference	NULL
in	NULL
the	NULL
qualitative	NULL
or	NULL
quantitative	NULL
binding	NULL
of	NULL
these	NULL
complexes	NULL
(	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
PMA/ionomycin	NULL
since	NULL
analysis	NULL
of	NULL
pGM600	NULL
induction	NULL
over	NULL
time	NULL
suggested	NULL
that	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
was	NULL
maximally	NULL
active	NULL
at	NULL
this	NULL
time	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
activation	NULL
of	NULL
cells	NULL
following	NULL
treatment	NULL
with	NULL
PMA	NULL
was	NULL
confirmed	NULL
by	NULL
measurement	NULL
of	NULL
secreted	NULL
interferon	NULL
y	NULL
in	NULL
the	NULL
media	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Hence	NULL
ETSl	NULL
binding	NULL
(	NULL
as	NULL
well	NULL
as	NULL
factors	NULL
A	NULL
and	NULL
B	NULL
)	NULL
appears	NULL
to	NULL
be	NULL
constitutive	NULL
over	NULL
the	NULL
time	NULL
frame	NULL
of	NULL
the	NULL
experiment	NULL
.	NULL

This	NULL
data	NULL
supports	NULL
the	NULL
hypothesis	NULL
that	NULL
,	NULL
although	NULL
PMA/ionomycin	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
provides	NULL
conditions	NULL
under	NULL
which	NULL
ETS1l	NULL
can	NULL
transactivate	NULL
GM-CSF	NULL
,	NULL
PMA/ionomycin	NULL
provides	NULL
required	NULL
ETS1l	NULL
co-factors	NULL
,	NULL
rather	NULL
than	NULL
directing	NULL
any	NULL
modification	NULL
of	NULL
ETSl	NULL
that	NULL
might	NULL
increase	NULL
its	NULL
binding	NULL
affinity	NULL
.	NULL

NFxB	NULL
p65/p50	NULL
and	NULL
p50/p50	NULL
complexes	NULL
bind	NULL
the	NULL
GM	NULL
CSF	NULL
promoter	NULL
following	NULL
PMA	NULL
and	NULL
ionomycin	NULL
stimulation	NULL
Two	NULL
NFxB-like	NULL
complexes	NULL
in	NULL
stimulated	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
(	NULL
complex	NULL
A	NULL
and	NULL
B	NULL
)	NULL
bound	NULL
the	NULL
GMxB	NULL
site	NULL
contained	NULL
within	NULL
the	NULL
CLE2/GC-box	NULL
region	NULL
,	NULL
-77	NULL
to	NULL
-85	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
Figure	NULL
4a	NULL
-	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Both	NULL
complexes	NULL
were	NULL
competed	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
a	NULL
consensus	NULL
NFxB	NULL
sequence	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
and	NULL
by	NULL
the	NULL
GMxB	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
mutant	NULL
GMxB	NULL
(	NULL
GMxBm1	NULL
)	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
labeled	NULL
GMxBml	NULL
did	NULL
not	NULL
bind	NULL
these	NULL
complexes	NULL
when	NULL
used	NULL
as	NULL
the	NULL
probe	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

The	NULL
consensus	NULL
NFxB	NULL
probe	NULL
bound	NULL
most	NULL
strongly	NULL
to	NULL
a	NULL
complex	NULL
in	NULL
stimulated	NULL
lysates	NULL
that	NULL
approximately	NULL
co-migrated	NULL
with	NULL
complex	NULL
A	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
they	NULL
are	NULL
equivalent	NULL
.	NULL

Binding	NULL
of	NULL
recombinant	NULL
p50	NULL
to	NULL
the	NULL
GMxB	NULL
site	NULL
was	NULL
correctly	NULL
identified	NULL
as	NULL
p50	NULL
using	NULL
a	NULL
panel	NULL
of	NULL
NFxB	NULL
family	NULL
antibodies	NULL
(	NULL
Figure	NULL
4b	NULL
-	NULL
lanes	NULL
2-6	NULL
)	NULL
.	NULL

Since	NULL
NFxB	NULL
factors	NULL
usually	NULL
bind	NULL
as	NULL
dimers	NULL
,	NULL
this	NULL
complex	NULL
most	NULL
probably	NULL
represents	NULL
a	NULL
p50/p50	NULL
homodimer	NULL
.	NULL

In	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
these	NULL
antibodies	NULL
identified	NULL
p50	NULL
in	NULL
both	NULL
complexes	NULL
A	NULL
and	NULL
B	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
and	NULL
p65	NULL
in	NULL
complex	NULL
A	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
complex	NULL
A	NULL
represents	NULL
a	NULL
p50/	NULL
p65	NULL
heterodimer	NULL
,	NULL
and	NULL
complex	NULL
B	NULL
a	NULL
p50/p50	NULL
homodimer	NULL
.	NULL

Additionally	NULL
,	NULL
both	NULL
recombinant	NULL
p50/p50	NULL
and	NULL
complex	NULL
B	NULL
had	NULL
a	NULL
similar	NULL
migration	NULL
rate	NULL
,	NULL
suggesting	NULL
that	NULL
they	NULL
are	NULL
equivalent	NULL
.	NULL

It	NULL
appeared	NULL
that	NULL
neither	NULL
IxB	NULL
nor	NULL
c-Rel	NULL
,	NULL
formed	NULL
part	NULL
of	NULL
the	NULL
nuclear	NULL
NFxB	NULL
complexes	NULL
that	NULL
bound	NULL
GMxB	NULL
,	NULL
since	NULL
the	NULL
binding	NULL
of	NULL
complexes	NULL
A	NULL
and	NULL
B	NULL
were	NULL
not	NULL
affected	NULL
by	NULL
addition	NULL
of	NULL
antibodies	NULL
to	NULL
these	NULL
proteins	NULL
(	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
2848	NULL
Binding	NULL
of	NULL
the	NULL
p50/p65	NULL
and	NULL
p50/p50	NULL
complexes	NULL
to	NULL
GMxB	NULL
were	NULL
not	NULL
detectable	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
,	NULL
but	NULL
were	NULL
strongly	NULL
induced	NULL
following	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
4	NULL
h	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Figure	NULL
4a	NULL
-	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
consensus	NULL
NFxB	NULL
sequence	NULL
did	NULL
however	NULL
display	NULL
some	NULL
binding	NULL
to	NULL
proteins	NULL
in	NULL
unstimulated	NULL
lysates	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
probably	NULL
due	NULL
to	NULL
its	NULL
very	NULL
high	NULL
affinity	NULL
compared	NULL
to	NULL
GMxB	NULL
.	NULL

These	NULL
complexes	NULL
displayed	NULL
similar	NULL
but	NULL
slightly	NULL
faster	NULL
and	NULL
slower	NULL
migration	NULL
rates	NULL
compared	NULL
to	NULL
the	NULL
p50/p65	NULL
complex	NULL
bound	NULL
to	NULL
GMxB	NULL
,	NULL
and	NULL
may	NULL
represent	NULL
binding	NULL
of	NULL
unidentified	NULL
NFxB	NULL
family	NULL
members	NULL
.	NULL

API	NULL
complexes	NULL
containing	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
,	NULL
and	NULL
other	NULL
fos	NULL
{	NULL
jun	NULL
family	NULL
members	NULL
,	NULL
bind	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
following	NULL
PMA	NULL
and	NULL
ionomycin	NULL
stimulation	NULL
APl-like	NULL
binding	NULL
to	NULL
the	NULL
GMAPI	NULL
sequence	NULL
contained	NULL
within	NULL
CLEO	NULL
,	NULL
-43	NULL
to	NULL
-50	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
was	NULL
represented	NULL
by	NULL
a	NULL
diffuse	NULL
band	NULL
in	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
(	NULL
Figure	NULL
Sa	NULL
-	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

This	NULL
complex	NULL
was	NULL
competed	NULL
by	NULL
an	NULL
excess	NULL
of	NULL
a	NULL
consensus	NULL
API	NULL
sequence	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
by	NULL
the	NULL
GMAPI	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
but	NULL
not	NULL
by	NULL
mutant	NULL
GMAPI	NULL
(	NULL
GMAPim	NULL
!	NULL

1l	NULL
)	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
labeled	NULL
GMAPIm	NULL
!	NULL

1	NULL
did	NULL
not	NULL
bind	NULL
this	NULL
complex	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
but	NULL
the	NULL
API	NULL
consensus	NULL
site	NULL
did	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

The	NULL
AP1	NULL
consensus	NULL
site	NULL
appears	NULL
to	NULL
bind	NULL
much	NULL
more	NULL
strongly	NULL
than	NULL
GMAPI	NULL
,	NULL
and	NULL
appeared	NULL
to	NULL
bind	NULL
additional	NULL
APIl-like	NULL
complexes	NULL
.	NULL

Recombinant	NULL
c-Fos	NULL
a	NULL
PROBE	NULL
GMxB	NULL
GMxBm1	NULL
-	NULL
cons	NULL
p50	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
PROTEIN	NULL
-	NULL
Pil	NULL
Pel	NULL
Piel	NULL
P+l	NULL
_-	NULL
Pel	NULL
-	NULL
P+	NULL
COMPETITOR	NULL
-	NULL
-	NULL
-	NULL
cons	NULL
xB	NULL
kBmi	NULL
-	NULL
-	NULL
-	NULL
10	NULL
20	NULL
3	NULL
40	NULL
50	NULL
60	NULL
70	NULL
8	NULL
9	NULL
10	NULL
comp	NULL
A-	NULL
l	NULL
P	NULL
u	NULL
comp	NULL
B-E1/SA	NULL
â	NULL
-	NULL
w=	NULL
mu	NULL
|	NULL
Read	NULL
th	NULL
|	NULL
Seat	NULL
Rusch	NULL
Reath	NULL
b	NULL
PROBE	NULL
GMxB	NULL
PROTEIN	NULL
Cont	NULL
p50	NULL
p50	NULL
p50	NULL
p50	NULL
p50	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
P+l	NULL
_	NULL
P+l	NULL
PA	NULL
PHI	NULL
P+	NULL
ANTIBODY	NULL
-	NULL
-	NULL
-	NULL
alkB	NULL
oRel	NULL
ap50up65	NULL
alcB	NULL
oRel	NULL
Â«	NULL
p50	NULL
ap65	NULL
10	NULL
20	NULL
3	NULL
40	NULL
50	NULL
60	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
-p	NULL
bro	NULL
p50/p6Â§S	NULL
p50/p50	NULL
-s-	NULL
WWW	NULL
wt	NULL
Figure	NULL
4	NULL
-	NULL
EMSA	NULL
analysis	NULL
of	NULL
the	NULL
NFxB	NULL
factors	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
GMxB	NULL
sequence	NULL
in	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
.	NULL

Probes	NULL
,	NULL
protein	NULL
samples	NULL
,	NULL
competitors	NULL
and	NULL
antibodies	NULL
are	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
consensus	NULL
NFxB	NULL
oligonucleotide	NULL
is	NULL
labeled	NULL
as	NULL
cons	NULL
.	NULL

GMxB	NULL
and	NULL
GMxBml	NULL
are	NULL
also	NULL
called	NULL
xB	NULL
and	NULL
xBm1l	NULL
,	NULL
respectively	NULL
.	NULL

NFxB	NULL
family	NULL
antibodies	NULL
include	NULL
those	NULL
to	NULL
IxB	NULL
,	NULL
Rel	NULL
,	NULL
p50	NULL
and	NULL
p65	NULL
.	NULL

Protein	NULL
samples	NULL
include	NULL
recombinant	NULL
p50	NULL
,	NULL
expressed	NULL
in	NULL
nuclear	NULL
lysates	NULL
of	NULL
transfected	NULL
COS	NULL
cells	NULL
,	NULL
control	NULL
(	NULL
Cont	NULL
)	NULL
COS	NULL
nuclear	NULL
lysates	NULL
transfected	NULL
with	NULL
pEFBOS	NULL
vector	NULL
,	NULL
and	NULL
Jurkat	NULL
(	NULL
Jur	NULL
)	NULL
nuclear	NULL
lysates	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
PMA/ionomycin	NULL
treated	NULL
(	NULL
P	NULL
+1	NULL
)	NULL
.	NULL

The	NULL
complexes	NULL
that	NULL
bind	NULL
GMxB	NULL
are	NULL
labeled	NULL
as	NULL
complex	NULL
A	NULL
or	NULL
p50/p65	NULL
,	NULL
complex	NULL
B	NULL
or	NULL
p50/p50	NULL
and	NULL
non-specific	NULL
(	NULL
n/s	NULL
)	NULL
.	NULL

The	NULL
open	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
antibody	NULL
super-shifted	NULL
NFxB	NULL
complexes	NULL
and	NULL
c-Jun	NULL
,	NULL
expressed	NULL
together	NULL
in	NULL
COS	NULL
cells	NULL
,	NULL
also	NULL
produced	NULL
a	NULL
diffuse	NULL
band	NULL
,	NULL
in	NULL
combination	NULL
with	NULL
API	NULL
factors	NULL
already	NULL
present	NULL
in	NULL
COS	NULL
nuclear	NULL
lysates	NULL
(	NULL
Figure	NULL
5b	NULL
-	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Cross-reacting	NULL
antibodies	NULL
to	NULL
Fos	NULL
(	NULL
pan-Fos	NULL
:	NULL
apfos	NULL
)	NULL
and	NULL
Jun	NULL
(	NULL
pan-Jun	NULL
:	NULL
apjun	NULL
)	NULL
family	NULL
members	NULL
,	NULL
demonstrated	NULL
that	NULL
most	NULL
or	NULL
all	NULL
of	NULL
the	NULL
complexes	NULL
present	NULL
contained	NULL
Fos/Jun	NULL
family	NULL
components	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

The	NULL
c-Fos	NULL
specific	NULL
antibody	NULL
appeared	NULL
to	NULL
remove	NULL
just	NULL
the	NULL
top	NULL
half	NULL
of	NULL
the	NULL
band	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

c-Jun	NULL
was	NULL
present	NULL
in	NULL
both	NULL
upper	NULL
and	NULL
lower	NULL
parts	NULL
of	NULL
the	NULL
band	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
results	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
binding	NULL
was	NULL
constituted	NULL
by	NULL
c-Fos/c-Jun	NULL
heterodimers	NULL
,	NULL
c-Jun/c-Jun	NULL
homodimers	NULL
and	NULL
other	NULL
Fos/Jun	NULL
family	NULL
complexes	NULL
.	NULL

These	NULL
experiments	NULL
verify	NULL
the	NULL
fidelity	NULL
of	NULL
the	NULL
antibodies	NULL
.	NULL

In	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
,	NULL
the	NULL
diffuse	NULL
band	NULL
appeared	NULL
to	NULL
contain	NULL
multiple	NULL
Fos/Jun	NULL
family	NULL
components	NULL
(	NULL
lanes	NULL
8	NULL
and	NULL
10	NULL
)	NULL
.	NULL

c-Fos	NULL
was	NULL
predominant	NULL
in	NULL
the	NULL
upper	NULL
part	NULL
of	NULL
the	NULL
band	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
and	NULL
c-Jun	NULL
in	NULL
the	NULL
lower	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
,	NULL
although	NULL
these	NULL
two	NULL
specific	NULL
components	NULL
also	NULL
appeared	NULL
to	NULL
contribute	NULL
to	NULL
both	NULL
upper	NULL
and	NULL
lower	NULL
portions	NULL
.	NULL

So	NULL
,	NULL
although	NULL
c-Fos/c-Jun	NULL
heterodimers	NULL
and	NULL
c-Jun/c-Jun	NULL
homodimers	NULL
appeared	NULL
to	NULL
be	NULL
present	NULL
in	NULL
the	NULL
band	NULL
,	NULL
other	NULL
Fos/Jun	NULL
family	NULL
dimers	NULL
were	NULL
also	NULL
present	NULL
.	NULL

The	NULL
PROBE	NULL
GMAP1	NULL
GMAP1m1	NULL
cons	NULL
Jur	NULL
-	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
PROTEIN	NULL
___	NULL
pil	NULL
Pil	NULL
Pil	NULL
Pe	NULL
-	NULL
-	NULL
P+	NULL
cee	NULL
5	NULL
&	NULL
A	NULL
COMPETITOR	NULL
o	NULL
<	NULL
<	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
AP1-complex	NULL
n/s-	NULL
Ind	NULL
bg	NULL
|	NULL
bcd	NULL
|	NULL
b	NULL
PROBE	NULL
GMAP1	NULL
Cont	NULL
Fos	NULL
Fos	NULL
Fos	NULL
Fos	NULL
Fos	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
Jur	NULL
PROTEIN	NULL
Jun	NULL
Jun	NULL
Jun	NULL
Jun	NULL
Jun	NULL
P+l	NULL
P+	NULL
PAI	NULL
P+	NULL
P+	NULL
w	NULL
w	NULL
&	NULL
c	NULL
PA	NULL
w	NULL
E	NULL
&	NULL
#	NULL
08	NULL
40	NULL
go	NULL
â¬	NULL
Â£04	NULL
g	NULL
a.	NULL
o	NULL
a.	NULL
o	NULL
a.	NULL
o	NULL
a.	NULL
o	NULL
ANTIBODY	NULL
_-	NULL
-	NULL
5	NULL
5	NULL
8	NULL
5	NULL
_-	NULL
5	NULL
8	NULL
8	NULL
8	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
-	NULL
>	NULL
Pj	NULL
&	NULL
=	NULL
led	NULL
APIO	NULL
}	NULL
wo	NULL
.	NULL

as	NULL
complexes	NULL
n/s	NULL
-	NULL
*	NULL
Figure	NULL
5	NULL
EMSA	NULL
analysis	NULL
of	NULL
the	NULL
API	NULL
factors	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
GMAP	NULL
sequence	NULL
in	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
.	NULL

Probes	NULL
,	NULL
protein	NULL
samples	NULL
,	NULL
antibodies	NULL
and	NULL
competitors	NULL
are	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
consensus	NULL
API	NULL
oligonucleotide	NULL
is	NULL
referred	NULL
to	NULL
as	NULL
cons	NULL
.	NULL

GMAPI	NULL
and	NULL
GMAPIm1l	NULL
are	NULL
also	NULL
called	NULL
API	NULL
and	NULL
APIm1	NULL
,	NULL
respectively	NULL
.	NULL

Protein	NULL
samples	NULL
include	NULL
recombinant	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
,	NULL
expressed	NULL
in	NULL
COS	NULL
nuclear	NULL
lysates	NULL
transfected	NULL
with	NULL
both	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
expression	NULL
constructs	NULL
,	NULL
control	NULL
(	NULL
Cont	NULL
)	NULL
,	NULL
COS	NULL
nuclear	NULL
lysates	NULL
transfected	NULL
with	NULL
pEFBOS	NULL
vector	NULL
,	NULL
and	NULL
Jurkat	NULL
(	NULL
Jur	NULL
)	NULL
nuclear	NULL
lysates	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
PMA/ionomycin	NULL
treated	NULL
(	NULL
P+1	NULL
)	NULL
.	NULL

apFos	NULL
and	NULL
apJun	NULL
are	NULL
pan-monoclonal	NULL
antibodies	NULL
that	NULL
recognise	NULL
multiple	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
members	NULL
,	NULL
respectively	NULL
.	NULL

acFos	NULL
and	NULL
a	NULL
Â«	NULL
cJun	NULL
monoclonal	NULL
antibodies	NULL
specifically	NULL
recognise	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
,	NULL
respectively	NULL
.	NULL

Complexes	NULL
that	NULL
bind	NULL
the	NULL
GMAP1	NULL
oligonucleotide	NULL
are	NULL
labeled	NULL
as	NULL
AP1	NULL
complexes	NULL
,	NULL
and	NULL
non-specific	NULL
(	NULL
n/s	NULL
)	NULL
.	NULL

The	NULL
open	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
antibody	NULL
super-shifted	NULL
API	NULL
complexes	NULL
diffuse	NULL
nature	NULL
of	NULL
the	NULL
API	NULL
complex	NULL
could	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
multiple	NULL
Fos/Jun	NULL
family	NULL
dimers	NULL
of	NULL
similar	NULL
EMSA	NULL
mobilities	NULL
(	NULL
Curran	NULL
and	NULL
Franza	NULL
,	NULL
1988	NULL
;	NULL
Kerppola	NULL
and	NULL
Curran	NULL
,	NULL
1995	NULL
)	NULL
,	NULL
although	NULL
the	NULL
presence	NULL
of	NULL
multiple	NULL
phosphorylated	NULL
and	NULL
non-phosphorylated	NULL
species	NULL
(	NULL
Radler-Pohl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Woodgett	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
could	NULL
also	NULL
contribute	NULL
to	NULL
the	NULL
diffuse	NULL
appearance	NULL
of	NULL
this	NULL
band	NULL
.	NULL

The	NULL
API	NULL
complexes	NULL
were	NULL
undetectable	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
,	NULL
but	NULL
were	NULL
induced	NULL
after	NULL
treatment	NULL
of	NULL
cells	NULL
for	NULL
4	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
Figure	NULL
Sa	NULL
-	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Although	NULL
,	NULL
using	NULL
a	NULL
stronger	NULL
API	NULL
binding	NULL
site	NULL
like	NULL
the	NULL
API	NULL
consensus	NULL
,	NULL
API	NULL
complexes	NULL
were	NULL
detected	NULL
at	NULL
lower	NULL
levels	NULL
in	NULL
lysates	NULL
from	NULL
unstimulated	NULL
cells	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Similarly	NULL
to	NULL
NFxB	NULL
binding	NULL
,	NULL
binding	NULL
of	NULL
API	NULL
complexes	NULL
present	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
to	NULL
the	NULL
API	NULL
consensus	NULL
displayed	NULL
similar	NULL
,	NULL
but	NULL
distinctly	NULL
different	NULL
mobilities	NULL
,	NULL
compared	NULL
to	NULL
those	NULL
that	NULL
bound	NULL
GMAPI	NULL
in	NULL
unstimulated	NULL
cells	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
ETS	NULL
,	NULL
NFB	NULL
and	NULL
API	NULL
binding	NULL
sites	NULL
reduce	NULL
GM-CSF	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
and	NULL
to	NULL
ETSI	NULL
transactivation	NULL
after	NULL
PMA	NULL
}	NULL
ionomycin	NULL
treatment	NULL
To	NULL
test	NULL
whether	NULL
the	NULL
ability	NULL
of	NULL
ETS1l	NULL
to	NULL
transactivate	NULL
in	NULL
PMA	NULL
/ionomycin	NULL
stimulated	NULL
cells	NULL
may	NULL
in	NULL
fact	NULL
be	NULL
due	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
NFB	NULL
and/or	NULL
API	NULL
factors	NULL
,	NULL
we	NULL
have	NULL
mutated	NULL
the	NULL
respective	NULL
binding	NULL
sites	NULL
for	NULL
these	NULL
factors	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
,	NULL
and	NULL
examined	NULL
the	NULL
effects	NULL
upon	NULL
PMA/	NULL
ionomycin	NULL
mediated	NULL
GM-CSF	NULL
transcription	NULL
,	NULL
and	NULL
ETS1	NULL
transactivation	NULL
following	NULL
PMA	NULL
treatment	NULL
.	NULL

The	NULL
modifications	NULL
to	NULL
pGM600	NULL
involve	NULL
minimal	NULL
point-mutations	NULL
,	NULL
analogous	NULL
to	NULL
those	NULL
found	NULL
in	NULL
the	NULL
mutant	NULL
oligonucleotides	NULL
GMETSm1	NULL
,	NULL
GMxBm1l	NULL
and	NULL
Fold	NULL
-	NULL
Treatment/	NULL
Transfection	NULL
Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
GMAPlm1l	NULL
,	NULL
that	NULL
we	NULL
have	NULL
demonstrated	NULL
disrupt	NULL
binding	NULL
of	NULL
the	NULL
respective	NULL
factors	NULL
(	NULL
Figures	NULL
3	NULL
,	NULL
4a	NULL
and	NULL
5b	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
ETS	NULL
,	NULL
NFxB	NULL
or	NULL
API	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
in	NULL
pGM600	NULL
resulted	NULL
in	NULL
very	NULL
little	NULL
change	NULL
to	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
expression	NULL
,	NULL
which	NULL
were	NULL
not	NULL
statistically	NULL
significant	NULL
(	NULL
1.2-	NULL
,	NULL
1.5-	NULL
and	NULL
1.4-fold	NULL
higher	NULL
than	NULL
wild-type	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

The	NULL
raw	NULL
CAT	NULL
data	NULL
for	NULL
each	NULL
construct	NULL
(	NULL
pGM600	NULL
,	NULL
pGM600-ETSm1	NULL
,	NULL
pGM600-xBm1	NULL
,	NULL
pGM600-APIm1	NULL
)	NULL
,	NULL
with	NULL
the	NULL
various	NULL
treatment/	NULL
co-transfections	NULL
,	NULL
was	NULL
normalised	NULL
to	NULL
its	NULL
own	NULL
basal	NULL
expression	NULL
,	NULL
which	NULL
was	NULL
given	NULL
the	NULL
value	NULL
of	NULL
'one	NULL
'	NULL
.	NULL

The	NULL
mean	NULL
of	NULL
at	NULL
least	NULL
four	NULL
replicates	NULL
for	NULL
each	NULL
experiment	NULL
was	NULL
graphed	NULL
to	NULL
show	NULL
a	NULL
'fold	NULL
induction	NULL
'	NULL
over	NULL
basal	NULL
expression	NULL
,	NULL
to	NULL
facilitate	NULL
comparison	NULL
between	NULL
the	NULL
different	NULL
mutations	NULL
and	NULL
treatment/co-transfections	NULL
.	NULL

All	NULL
of	NULL
these	NULL
mutations	NULL
resulted	NULL
in	NULL
reduction	NULL
or	NULL
abolition	NULL
of	NULL
PMA	NULL
responsiveness	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
regions	NULL
of	NULL
the	NULL
promoter	NULL
are	NULL
important	NULL
for	NULL
GM-CSF	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Figure	NULL
6	NULL
,	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
ETS	NULL
site	NULL
in	NULL
CLEO	NULL
(	NULL
pGM600-ETSm1	NULL
)	NULL
abolished	NULL
PMA/ionomycin	NULL
inducibility	NULL
and	NULL
also	NULL
ETSl	NULL
transactivation	NULL
following	NULL
PMA	NULL
treatment	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
NFxB	NULL
site	NULL
in	NULL
the	NULL
CLE2/	NULL
GC-box	NULL
and	NULL
API	NULL
site	NULL
in	NULL
CLEO	NULL
(	NULL
pGM600-APim1	NULL
)	NULL
resulted	NULL
in	NULL
1.4-	NULL
and	NULL
1.6-fold	NULL
PMA/	NULL
ionomycin	NULL
induction	NULL
,	NULL
respectively	NULL
,	NULL
which	NULL
were	NULL
not	NULL
statistically	NULL
different	NULL
to	NULL
basal	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mutations	NULL
resulted	NULL
in	NULL
35	NULL
%	NULL
and	NULL
40	NULL
%	NULL
of	NULL
the	NULL
pGM600	NULL
induction	NULL
by	NULL
PMA	NULL
respectively	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
NFxB	NULL
and	NULL
mutations	NULL
greatly	NULL
reduced	NULL
the	NULL
ability	NULL
of	NULL
ETSl	NULL
to	NULL
transactivate	NULL
,	NULL
supporting	NULL
the	NULL
proposal	NULL
that	NULL
the	NULL
PMA	NULL
dependence	NULL
of	NULL
ETSI	NULL
transactivation	NULL
is	NULL
in	NULL
fact	NULL
due	NULL
to	NULL
dependence	NULL
on	NULL
PMA/ionomycin	NULL
inducible	NULL
co-factors	NULL
such	NULL
as	NULL
NFxB	NULL
and	NULL
API	NULL
.	NULL

Relative	NULL
CAT	NULL
Activity	NULL
(	NULL
Fold	NULL
Induction	NULL
)	NULL
1.0	NULL
1.0	NULL
cont	NULL
13	NULL
WBF	NULL
ncusoo	NULL
&	NULL
pomsoo-ETSm1	NULL
3.2	NULL
Â§	NULL
pemsoo	NULL
Â«	NULL
Bmi	NULL
ag	NULL
_	NULL
ETS	NULL
EZ	NULL
pomsoo-APim1	NULL
11	NULL
3.9	NULL
0.8	NULL
1.4	NULL
P+l	NULL
1.6	NULL
15	NULL
0.6	NULL
P+l	NULL
3.3	NULL
ETS1	NULL
2.6	NULL
Figure	NULL
6	NULL
CAT	NULL
analysis	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
ETS1	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
mutations	NULL
of	NULL
pGM600	NULL
on	NULL
PMA/ionomycin	NULL
induction	NULL
and	NULL
ETS1	NULL
transactivation	NULL
with	NULL
PMA/ionomycin	NULL
.	NULL

The	NULL
structures	NULL
of	NULL
the	NULL
mutant	NULL
GM-CSF	NULL
promoter	NULL
constructs	NULL
are	NULL
shown	NULL
schematically	NULL
,	NULL
with	NULL
the	NULL
bar	NULL
pattern	NULL
used	NULL
to	NULL
represent	NULL
each	NULL
(	NULL
inset	NULL
)	NULL
.	NULL

Relative	NULL
CAT	NULL
activities/fold	NULL
induction	NULL
were	NULL
calculated	NULL
from	NULL
raw	NULL
CAT	NULL
data	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

Other	NULL
labels	NULL
and	NULL
procedures	NULL
are	NULL
as	NULL
described	NULL
in	NULL
Figure	NULL
2	NULL
2849	NULL
Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
2850	NULL
Synergistic	NULL
cooperation	NULL
between	NULL
ETS	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
is	NULL
reduced	NULL
by	NULL
mutations	NULL
in	NULL
their	NULL
binding	NULL
sites	NULL
Although	NULL
ETS1l	NULL
activity	NULL
seems	NULL
to	NULL
be	NULL
dependent	NULL
upon	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
factors	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
NFxB	NULL
and	NULL
API	NULL
to	NULL
transactivate	NULL
may	NULL
also	NULL
be	NULL
dependent	NULL
on	NULL
other	NULL
constitutive	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
ETSI	NULL
,	NULL
that	NULL
are	NULL
already	NULL
present	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
To	NULL
test	NULL
the	NULL
interdependence	NULL
of	NULL
the	NULL
ETSl	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
factors	NULL
,	NULL
and	NULL
whether	NULL
these	NULL
factors	NULL
act	NULL
directly	NULL
through	NULL
their	NULL
respective	NULL
binding	NULL
sites	NULL
,	NULL
we	NULL
analysed	NULL
ETS1	NULL
,	NULL
NFB	NULL
and	NULL
API	NULL
transactivation	NULL
,	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
with	NULL
the	NULL
promoter	NULL
constructs	NULL
containing	NULL
mutations	NULL
of	NULL
their	NULL
binding	NULL
sites	NULL
(	NULL
Figure	NULL
7	NULL
,	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Transactivation	NULL
with	NULL
NFxB	NULL
was	NULL
reduced	NULL
by	NULL
approximately	NULL
90	NULL
%	NULL
,	NULL
from	NULL
18-	NULL
to	NULL
1.9-fold	NULL
,	NULL
after	NULL
the	NULL
NFxB	NULL
site	NULL
has	NULL
been	NULL
mutated	NULL
,	NULL
and	NULL
API	NULL
transactivation	NULL
(	NULL
8.8-fold	NULL
)	NULL
was	NULL
abolished	NULL
with	NULL
an	NULL
API	NULL
mutation	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
these	NULL
factors	NULL
,	NULL
alone	NULL
,	NULL
is	NULL
achieved	NULL
mainly	NULL
through	NULL
direct	NULL
interaction	NULL
with	NULL
the	NULL
promoter	NULL
.	NULL

However	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
ETS	NULL
site	NULL
reduced	NULL
NFxB	NULL
transactivation	NULL
by	NULL
63	NULL
%	NULL
,	NULL
to	NULL
6.6-fold	NULL
(	NULL
P=0.01	NULL
)	NULL
,	NULL
and	NULL
blocked	NULL
API	NULL
mediated	NULL
transactivation	NULL
completely	NULL
,	NULL
suggesting	NULL
that	NULL
exogenous	NULL
NFxB	NULL
and	NULL
API	NULL
functionally	NULL
interact	NULL
with	NULL
endogenous	NULL
factor/s	NULL
in	NULL
Jurkat	NULL
cells	NULL
that	NULL
bind	NULL
the	NULL
ETS	NULL
site	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
ETS	NULL
binding	NULL
site	NULL
also	NULL
eliminated	NULL
the	NULL
ability	NULL
of	NULL
ETS1	NULL
to	NULL
transactivate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
or	NULL
both	NULL
NFxB	NULL
and	NULL
API	NULL
,	NULL
indicating	NULL
that	NULL
ETS1l	NULL
acts	NULL
by	NULL
binding	NULL
directly	NULL
to	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
at	NULL
this	NULL
site	NULL
.	NULL

The	NULL
synergistic	NULL
transactivation	NULL
displayed	NULL
by	NULL
ETSIl	NULL
and	NULL
NFxB	NULL
together	NULL
(	NULL
123-fold	NULL
)	NULL
was	NULL
reduced	NULL
by	NULL
94	NULL
%	NULL
,	NULL
to	NULL
7.3-fold	NULL
,	NULL
by	NULL
mutation	NULL
of	NULL
the	NULL
ETS	NULL
binding	NULL
site	NULL
,	NULL
and	NULL
by	NULL
97	NULL
%	NULL
,	NULL
to	NULL
fourfold	NULL
,	NULL
by	NULL
mutation	NULL
of	NULL
the	NULL
NFxB	NULL
binding	NULL
site	NULL
.	NULL

These	NULL
mutations	NULL
did	NULL
not	NULL
however	NULL
completely	NULL
block	NULL
transactivation	NULL
,	NULL
possibly	NULL
because	NULL
there	NULL
is	NULL
still	NULL
residual	NULL
binding	NULL
to	NULL
the	NULL
mutated	NULL
sites	NULL
,	NULL
although	NULL
this	NULL
is	NULL
not	NULL
supported	NULL
by	NULL
the	NULL
EMSA	NULL
data	NULL
(	NULL
Figures	NULL
3	NULL
-	NULL
lane	NULL
7	NULL
and	NULL
4	NULL
-	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
an	NULL
additional	NULL
p65	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
CK1	NULL
element	NULL
(	NULL
Shannon	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Himes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
NFxB	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
CLE2/GC-box	NULL
region	NULL
,	NULL
and	NULL
an	NULL
additional	NULL
ETS1	NULL
binding	NULL
Fold	NULL
-	NULL
Transfection	NULL
Relative	NULL
CAT	NULL
Activity	NULL
(	NULL
Fold	NULL
Induction	NULL
)	NULL
o	NULL
2	NULL
2	NULL
3	NULL
5	NULL
5	NULL
5	NULL
\p	NULL
1.0	NULL
No	NULL
1.0	NULL
Â®	NULL
1.0	NULL
cont	NULL
1.0	NULL
:	NULL
RF	NULL
pcusoo	NULL
wae	NULL
0.8	NULL
H	NULL
pomsoo-ETSm1	NULL
==	NULL
gg	NULL
ETS1	NULL
g	NULL
pGM600-	NULL
Â«	NULL
Bmt	NULL
-	NULL
==	NULL
11	NULL
R	NULL
BBJ	NULL
pomso0-APim1i	NULL
==	NULL
[	NULL
Brd	NULL
]	NULL
18	NULL
6.6	NULL
1.9	NULL
NFB	NULL
{	NULL
8.3	NULL
123	NULL
7.3	NULL
-	NULL
NFB	NULL
as	NULL
4.0	NULL
ETS1	NULL
8.8	NULL
11	NULL
1	NULL
AP1	NULL
3	NULL
p	NULL
0.5	NULL
34	NULL
0.8	NULL
AP1	NULL
3.1	NULL
ETS1	NULL
S	NULL
0.4	NULL
308	NULL
51	NULL
NFB	NULL
42	NULL
AP1	NULL
3.0	NULL
820	NULL
_	NULL
wreB	NULL
_	NULL
\	NULL
64	NULL
AP1	NULL
970	NULL
ers	NULL
==	NULL
6.5	NULL
sas	NULL
Figure	NULL
7	NULL
-	NULL
CAT	NULL
analysis	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
ETS1	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
mutations	NULL
of	NULL
pGM600	NULL
on	NULL
ETS1	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
transactivational	NULL
synergy	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
unstimulated	NULL
.	NULL

The	NULL
structures	NULL
of	NULL
the	NULL
mutant	NULL
GM-CSF	NULL
promoter	NULL
constructs	NULL
are	NULL
shown	NULL
schematically	NULL
,	NULL
with	NULL
the	NULL
bar	NULL
pattern	NULL
used	NULL
to	NULL
represent	NULL
each	NULL
(	NULL
inset	NULL
)	NULL
.	NULL

Relative	NULL
CAT	NULL
activities/fold	NULL
induction	NULL
were	NULL
calculated	NULL
from	NULL
raw	NULL
CAT	NULL
data	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

Other	NULL
labels	NULL
and	NULL
procedures	NULL
are	NULL
as	NULL
described	NULL
in	NULL
Figure	NULL
2	NULL
Table	NULL
1	NULL
Tabulation	NULL
of	NULL
CAT	NULL
data	NULL
for	NULL
pGM600	NULL
and	NULL
all	NULL
mutant	NULL
constructs	NULL
Treatment	NULL
!	NULL

Relative	NULL
CAT	NULL
Activity	NULL
(	NULL
mean	NULL
)	NULL
transcription	NULL
pGM600-	NULL
-	NULL
pGM600-	NULL
-	NULL
pGM600-factor	NULL
pGM600	NULL
ETSm1	NULL
xBm1	NULL
APim1	NULL
control	NULL
1.0	NULL
1.0	NULL
1.0	NULL
1.0	NULL
ETSI	NULL
0.8	NULL
0.6	NULL
0.9	NULL
1.1	NULL
P+I	NULL
3.9	NULL
0.8	NULL
1.4	NULL
1.6	NULL
P+1I	NULL
ETSl	NULL
15	NULL
0.6	NULL
3.3	NULL
2.6	NULL
NFB	NULL
18	NULL
6.6	NULL
1.9	NULL
8.3	NULL
NFxB	NULL
ETS1	NULL
123	NULL
7.3	NULL
4.0	NULL
18	NULL
API	NULL
8.8	NULL
1.1	NULL
1.1	NULL
0.5	NULL
API	NULL
ETSl	NULL
34	NULL
0.8	NULL
3.1	NULL
0.4	NULL
NFxB	NULL
API	NULL
308	NULL
51	NULL
42	NULL
3.0	NULL
NFxB	NULL
API	NULL
ETSI	NULL
820	NULL
64	NULL
97	NULL
6.5	NULL
site	NULL
approximately	NULL
-300	NULL
bp	NULL
from	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
could	NULL
have	NULL
contributed	NULL
to	NULL
the	NULL
remaining	NULL
NFxB	NULL
transactivation	NULL
.	NULL

The	NULL
synergistic	NULL
transactivation	NULL
displayed	NULL
by	NULL
ETS1l	NULL
and	NULL
API	NULL
together	NULL
(	NULL
34-fold	NULL
)	NULL
was	NULL
abolished	NULL
by	NULL
mutation	NULL
of	NULL
either	NULL
the	NULL
ETS	NULL
or	NULL
the	NULL
API	NULL
binding	NULL
sites	NULL
.	NULL

Because	NULL
the	NULL
ETS	NULL
and	NULL
API	NULL
binding	NULL
sites	NULL
are	NULL
very	NULL
close	NULL
together	NULL
in	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
the	NULL
respective	NULL
mutations	NULL
were	NULL
evaluated	NULL
by	NULL
EMSA	NULL
,	NULL
which	NULL
confirmed	NULL
that	NULL
mutation	NULL
in	NULL
one	NULL
binding	NULL
site	NULL
did	NULL
not	NULL
disrupt	NULL
or	NULL
modify	NULL
binding	NULL
to	NULL
the	NULL
other	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
strong	NULL
synergy	NULL
displayed	NULL
by	NULL
co-transfection	NULL
of	NULL
ETSl	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
together	NULL
(	NULL
820-fold	NULL
)	NULL
was	NULL
particularly	NULL
dependent	NULL
upon	NULL
an	NULL
intact	NULL
API	NULL
site	NULL
(	NULL
reducing	NULL
transactivation	NULL
by	NULL
99	NULL
%	NULL
,	NULL
to	NULL
6.5-fold	NULL
,	NULL
when	NULL
mutated	NULL
)	NULL
,	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
the	NULL
ETS	NULL
and	NULL
NFxB	NULL
binding	NULL
sites	NULL
(	NULL
reducing	NULL
transactivation	NULL
by	NULL
92	NULL
%	NULL
,	NULL
to	NULL
64-fold	NULL
and	NULL
88	NULL
%	NULL
,	NULL
to	NULL
97-fold	NULL
,	NULL
respectively	NULL
,	NULL
upon	NULL
mutation	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
results	NULL
from	NULL
ETS	NULL
NFxB	NULL
and	NULL
API	NULL
mutations	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
suggest	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
transactivational	NULL
interdependence	NULL
between	NULL
these	NULL
factors	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
although	NULL
NFB	NULL
and	NULL
API	NULL
appear	NULL
to	NULL
have	NULL
some	NULL
ability	NULL
to	NULL
operate	NULL
independently	NULL
,	NULL
these	NULL
experiments	NULL
suggest	NULL
that	NULL
there	NULL
is	NULL
interactivity	NULL
with	NULL
endogenous	NULL
ETS1l	NULL
,	NULL
or	NULL
other	NULL
ETS	NULL
factors	NULL
,	NULL
that	NULL
are	NULL
expressed	NULL
constitutively	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

Discussion	NULL
Helper	NULL
T	NULL
cells	NULL
are	NULL
intimately	NULL
involved	NULL
in	NULL
mediating	NULL
immune	NULL
responses	NULL
to	NULL
pathogens	NULL
and	NULL
tumours	NULL
.	NULL

Recognition	NULL
of	NULL
antigens	NULL
is	NULL
followed	NULL
by	NULL
a	NULL
process	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
which	NULL
ultimately	NULL
results	NULL
in	NULL
expression	NULL
and	NULL
secretion	NULL
of	NULL
cytokines	NULL
that	NULL
enhance	NULL
the	NULL
function	NULL
of	NULL
various	NULL
effector	NULL
cells	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
these	NULL
cytokines	NULL
is	NULL
primarily	NULL
mediated	NULL
through	NULL
increased	NULL
transcription	NULL
factor	NULL
activity	NULL
and	NULL
subsequent	NULL
transcription	NULL
.	NULL

Initially	NULL
,	NULL
our	NULL
study	NULL
of	NULL
GM	NULL
CSF	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
suggested	NULL
that	NULL
ETSI	NULL
,	NULL
a	NULL
constitutively	NULL
expressed	NULL
transcription	NULL
factor	NULL
,	NULL
was	NULL
required	NULL
for	NULL
GM-CSF	NULL
transcription	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
this	NULL
factor	NULL
could	NULL
only	NULL
transactivate	NULL
GM-CSF	NULL
in	NULL
T	NULL
cells	NULL
that	NULL
had	NULL
first	NULL
been	NULL
activated	NULL
by	NULL
PMA	NULL
/ionomycin	NULL
treatment	NULL
.	NULL

In	NULL
this	NULL
paper	NULL
we	NULL
show	NULL
that	NULL
ETSl	NULL
can	NULL
transactivate	NULL
GM-CSF	NULL
in	NULL
unstimulated	NULL
cells	NULL
,	NULL
provided	NULL
that	NULL
NFxB	NULL
or	NULL
API	NULL
transcription	NULL
factors	NULL
Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
are	NULL
supplied	NULL
.	NULL

We	NULL
confirm	NULL
previous	NULL
studies	NULL
which	NULL
demonstrate	NULL
that	NULL
NFxB	NULL
and	NULL
API	NULL
factors	NULL
are	NULL
induced	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
factors	NULL
are	NULL
the	NULL
PMA/ionomycin	NULL
induced	NULL
co-factors	NULL
required	NULL
for	NULL
ETS1	NULL
transactivation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
transactivation	NULL
with	NULL
combinations	NULL
of	NULL
ETSI	NULL
,	NULL
NFB	NULL
and	NULL
API	NULL
is	NULL
highly	NULL
synergistic	NULL
and	NULL
interdependent	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
factors	NULL
interact	NULL
as	NULL
a	NULL
higher	NULL
order	NULL
transcriptional	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
ETS1	NULL
could	NULL
not	NULL
transactivate	NULL
a	NULL
GM-CSF	NULL
promoter	NULL
reporter	NULL
construct	NULL
co-transfected	NULL
into	NULL
unstimulated	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
both	NULL
NFxB	NULL
(	NULL
p50	NULL
and	NULL
p65	NULL
)	NULL
and	NULL
AP1	NULL
(	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
)	NULL
could	NULL
.	NULL

However	NULL
,	NULL
co-transfection	NULL
of	NULL
ETSl	NULL
with	NULL
either	NULL
or	NULL
both	NULL
NFxB	NULL
and	NULL
API	NULL
resulted	NULL
in	NULL
additional	NULL
,	NULL
or	NULL
synergistic	NULL
,	NULL
transactivation	NULL
,	NULL
which	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
achieved	NULL
by	NULL
co-transfection	NULL
of	NULL
ETSI	NULL
into	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Additionally	NULL
,	NULL
mutations	NULL
designed	NULL
to	NULL
eliminate	NULL
binding	NULL
of	NULL
NFxB	NULL
or	NULL
API	NULL
reduced	NULL
the	NULL
ability	NULL
of	NULL
PMA	NULL
/ionomycin	NULL
to	NULL
induce	NULL
GM-CSF	NULL
transcription	NULL
(	NULL
as	NULL
did	NULL
an	NULL
ETS	NULL
mutation	NULL
)	NULL
.	NULL

These	NULL
mutations	NULL
also	NULL
significantly	NULL
reduced	NULL
the	NULL
ability	NULL
of	NULL
ETSl	NULL
to	NULL
transactivate	NULL
GM-CSF	NULL
in	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Binding	NULL
of	NULL
endogenous	NULL
ETS1	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
was	NULL
constitutive	NULL
,	NULL
and	NULL
NFxB	NULL
and	NULL
API	NULL
were	NULL
induced	NULL
,	NULL
following	NULL
PMA/ionomycin	NULL
treatment	NULL
(	NULL
also	NULL
discussed	NULL
later	NULL
)	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
;	NULL
(	NULL
1	NULL
)	NULL
constitutive	NULL
ETS1l	NULL
and	NULL
induced	NULL
NFxB	NULL
and	NULL
API	NULL
are	NULL
necessary	NULL
for	NULL
PMA/ionomycin	NULL
mediated	NULL
GM-CSF	NULL
expression	NULL
;	NULL
(	NULL
2	NULL
)	NULL
PMA/ionomycin	NULL
induces	NULL
co-factors	NULL
required	NULL
for	NULL
ETSl	NULL
activity	NULL
rather	NULL
than	NULL
directing	NULL
any	NULL
modification	NULL
of	NULL
ETS1	NULL
and	NULL
might	NULL
increase	NULL
its	NULL
binding	NULL
affinity	NULL
;	NULL
and	NULL
(	NULL
3	NULL
)	NULL
that	NULL
these	NULL
factors	NULL
are	NULL
NFxB	NULL
and/or	NULL
API	NULL
.	NULL

The	NULL
concept	NULL
that	NULL
ETS1l	NULL
may	NULL
act	NULL
only	NULL
in	NULL
coordination	NULL
with	NULL
transcriptional	NULL
partners	NULL
is	NULL
supported	NULL
by	NULL
a	NULL
recent	NULL
study	NULL
that	NULL
has	NULL
identified	NULL
a	NULL
link	NULL
between	NULL
ETSI	NULL
transactivation	NULL
of	NULL
the	NULL
TIMP-1	NULL
promoter	NULL
and	NULL
its	NULL
requirement	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
API	NULL
(	NULL
Logan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
another	NULL
recently	NULL
published	NULL
paper	NULL
has	NULL
found	NULL
that	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
can	NULL
be	NULL
transactivated	NULL
by	NULL
ETSl	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
(	NULL
Nimer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
which	NULL
conflicts	NULL
with	NULL
the	NULL
data	NULL
presented	NULL
here	NULL
.	NULL

Their	NULL
study	NULL
involved	NULL
the	NULL
use	NULL
of	NULL
a	NULL
truncated	NULL
promoter	NULL
in	NULL
which	NULL
the	NULL
NFxB	NULL
,	NULL
Spl	NULL
,	NULL
CBF	NULL
,	NULL
and	NULL
possibly	NULL
API	NULL
and	NULL
YY1	NULL
binding	NULL
sites	NULL
,	NULL
of	NULL
the	NULL
full-length	NULL
promoter	NULL
,	NULL
are	NULL
missing	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
ETS1l	NULL
requires	NULL
other	NULL
co-factors	NULL
for	NULL
transactivation	NULL
,	NULL
there	NULL
may	NULL
also	NULL
be	NULL
inhibitory	NULL
mechanisms	NULL
that	NULL
operate	NULL
through	NULL
the	NULL
full	NULL
length	NULL
promoter	NULL
that	NULL
prevent	NULL
ETS1	NULL
from	NULL
transactivating	NULL
alone	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
at	NULL
least	NULL
three	NULL
ETS-like	NULL
factors	NULL
in	NULL
Jurkat	NULL
nuclear	NULL
lysates	NULL
bound	NULL
the	NULL
ETS	NULL
site	NULL
of	NULL
CLEO	NULL
in	NULL
the	NULL
proximal	NULL
GM-CSF	NULL
promoter	NULL
.	NULL

These	NULL
factors	NULL
,	NULL
including	NULL
ETSI	NULL
,	NULL
displayed	NULL
high	NULL
levels	NULL
of	NULL
constitutive	NULL
binding	NULL
,	NULL
before	NULL
and	NULL
after	NULL
4	NULL
h	NULL
of	NULL
PMA/ionomycin	NULL
treatment	NULL
.	NULL

In	NULL
a	NULL
previous	NULL
publication	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
we	NULL
have	NULL
elaborated	NULL
further	NULL
upon	NULL
ETSl	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
and	NULL
provide	NULL
evidence	NULL
to	NULL
suggest	NULL
that	NULL
ETSI	NULL
specifically	NULL
is	NULL
required	NULL
for	NULL
GM-CSF	NULL
transcription	NULL
following	NULL
T	NULL
cell	NULL
stimulation	NULL
with	NULL
PMA/ionomycin	NULL
.	NULL

However	NULL
,	NULL
some	NULL
controversy	NULL
exists	NULL
as	NULL
to	NULL
whether	NULL
ETSI	NULL
can	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
genes	NULL
induced	NULL
by	NULL
T	NULL
cell	NULL
activation	NULL
since	NULL
ETSl	NULL
mRNA	NULL
and	NULL
protein	NULL
levels	NULL
are	NULL
reduced	NULL
following	NULL
activation	NULL
signals	NULL
(	NULL
Bhat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Romano-Spica	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
2851	NULL
Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
2852	NULL
binding	NULL
activity	NULL
of	NULL
pSl	NULL
ETSl	NULL
can	NULL
be	NULL
reduced	NULL
by	NULL
calcium	NULL
dependent	NULL
phosphorylation	NULL
(	NULL
Fisher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Rabault	NULL
and	NULL
Ghysdael	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
ETS1l	NULL
can	NULL
act	NULL
as	NULL
a	NULL
repressor	NULL
and	NULL
contributes	NULL
to	NULL
IL-2	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
due	NULL
to	NULL
a	NULL
consequent	NULL
reduction	NULL
in	NULL
its	NULL
binding	NULL
(	NULL
Romano-Spica	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

We	NULL
believe	NULL
that	NULL
the	NULL
consequences	NULL
of	NULL
these	NULL
considerations	NULL
are	NULL
allayed	NULL
by	NULL
the	NULL
following	NULL
points	NULL
:	NULL
(	NULL
1	NULL
)	NULL
the	NULL
reduction	NULL
in	NULL
ETS1l	NULL
protein	NULL
levels	NULL
only	NULL
occurs	NULL
relatively	NULL
late	NULL
in	NULL
the	NULL
activation	NULL
process	NULL
,	NULL
due	NULL
to	NULL
changes	NULL
in	NULL
de	NULL
novo	NULL
synthesis	NULL
(	NULL
Romano-Spica	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
(	NULL
2	NULL
)	NULL
although	NULL
phosphorylation	NULL
occurs	NULL
quickly	NULL
(	NULL
within	NULL
5	NULL
min	NULL
)	NULL
,	NULL
the	NULL
alternatively	NULL
spliced	NULL
p42	NULL
ETSI	NULL
product	NULL
,	NULL
expressed	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
lacks	NULL
this	NULL
inhibitory	NULL
phosphorylation	NULL
domain	NULL
(	NULL
Koizumi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Fisher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
;	NULL
(	NULL
3	NULL
)	NULL
other	NULL
phosphorylation	NULL
sites	NULL
present	NULL
in	NULL
both	NULL
forms	NULL
of	NULL
ETSl	NULL
have	NULL
been	NULL
linked	NULL
to	NULL
enhanced	NULL
transactivator	NULL
activity	NULL
(	NULL
Bradford	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Yang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
;	NULL
(	NULL
4	NULL
)	NULL
inactivation	NULL
of	NULL
the	NULL
ets	NULL
!	NULL

gene	NULL
in	NULL
mice	NULL
results	NULL
in	NULL
T	NULL
cells	NULL
that	NULL
display	NULL
severe	NULL
proliferative	NULL
defects	NULL
in	NULL
response	NULL
to	NULL
activating	NULL
signals	NULL
(	NULL
Muthusamy	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
which	NULL
indicates	NULL
that	NULL
ETS1l	NULL
is	NULL
required	NULL
for	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Thus	NULL
several	NULL
lines	NULL
of	NULL
evidence	NULL
,	NULL
including	NULL
the	NULL
data	NULL
presented	NULL
here	NULL
,	NULL
suggest	NULL
that	NULL
ETSI	NULL
can	NULL
be	NULL
involved	NULL
in	NULL
transcription	NULL
of	NULL
genes	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Possibly	NULL
,	NULL
ETS1	NULL
function	NULL
is	NULL
attenuated	NULL
late	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
via	NULL
negative	NULL
feedback	NULL
mechanisms	NULL
.	NULL

Binding	NULL
of	NULL
NFxB	NULL
and	NULL
API	NULL
factors	NULL
to	NULL
their	NULL
respective	NULL
binding	NULL
sites	NULL
in	NULL
CLE2/GC-box	NULL
and	NULL
CLEO	NULL
of	NULL
the	NULL
GM	NULL
CSF	NULL
promoter	NULL
were	NULL
undetectable	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
but	NULL
were	NULL
strongly	NULL
induced	NULL
upon	NULL
4	NULL
h	NULL
of	NULL
PMA/ionomycin	NULL
treatment	NULL
.	NULL

The	NULL
induced	NULL
NFxB	NULL
complexes	NULL
were	NULL
identified	NULL
as	NULL
p50/p50	NULL
homodimers	NULL
and	NULL
p50/	NULL
p65	NULL
heterodimers	NULL
,	NULL
and	NULL
multiple	NULL
API	NULL
complexes	NULL
were	NULL
constituted	NULL
by	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
members	NULL
including	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
p50/p65	NULL
constitutes	NULL
a	NULL
transcriptionally	NULL
active	NULL
complex	NULL
(	NULL
Schmitz	NULL
and	NULL
Baeuerle	NULL
,	NULL
1991	NULL
)	NULL
,	NULL
and	NULL
the	NULL
different	NULL
API	NULL
dimers	NULL
may	NULL
exhibit	NULL
varying	NULL
positive	NULL
or	NULL
negative	NULL
transactivating	NULL
properties	NULL
(	NULL
Deng	NULL
and	NULL
Karin	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
confirm	NULL
and	NULL
extend	NULL
the	NULL
findings	NULL
of	NULL
others	NULL
who	NULL
have	NULL
analysed	NULL
binding	NULL
to	NULL
the	NULL
GMxB	NULL
and	NULL
GMAPI	NULL
sites	NULL
(	NULL
Boise	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Himes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
and	NULL
provide	NULL
clues	NULL
as	NULL
to	NULL
which	NULL
NFxB	NULL
and	NULL
API	NULL
family	NULL
members	NULL
may	NULL
synergise	NULL
with	NULL
ETSl	NULL
in	NULL
vivo	NULL
.	NULL

NFxB	NULL
complexes	NULL
are	NULL
normally	NULL
sequestered	NULL
in	NULL
the	NULL
cytoplasm	NULL
as	NULL
precursors	NULL
or	NULL
by	NULL
binding	NULL
IxB	NULL
(	NULL
Beg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Finco	NULL
and	NULL
Baldwin	NULL
,	NULL
1995	NULL
)	NULL
,	NULL
an	NULL
association	NULL
that	NULL
is	NULL
known	NULL
to	NULL
be	NULL
disrupted	NULL
by	NULL
PKC	NULL
mediated	NULL
phosphorylation	NULL
and	NULL
proteolysis	NULL
of	NULL
IxB	NULL
and	NULL
p105	NULL
(	NULL
the	NULL
p50	NULL
precursor	NULL
)	NULL
(	NULL
Israel	NULL
,	NULL
1995	NULL
;	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Verma	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
p50	NULL
also	NULL
results	NULL
in	NULL
a	NULL
higher	NULL
level	NULL
of	NULL
DNA	NULL
binding	NULL
stability	NULL
(	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
and	NULL
increased	NULL
p105	NULL
transcription	NULL
is	NULL
mediated	NULL
by	NULL
PMA	NULL
(	NULL
Meyer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Cogswell	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

All	NULL
of	NULL
these	NULL
mechanisms	NULL
are	NULL
potentially	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
NFxB	NULL
binding	NULL
observed	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
API	NULL
binding	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
was	NULL
probably	NULL
mediated	NULL
by	NULL
PKC/Ca	NULL
``	NULL
+	NULL
dependent	NULL
phosphorylation	NULL
dephosphorylation	NULL
and	NULL
consequent	NULL
increased	NULL
binding	NULL
affinity	NULL
(	NULL
Boyle	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Karin	NULL
,	NULL
1995	NULL
)	NULL
,	NULL
and	NULL
by	NULL
increased	NULL
transcription	NULL
of	NULL
Fos/Jun	NULL
family	NULL
members	NULL
(	NULL
Makover	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Rincon	NULL
and	NULL
Flavell	NULL
,	NULL
1994	NULL
;	NULL
Janknecht	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
both	NULL
NFxB	NULL
and	NULL
API	NULL
binding	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
increase	NULL
shortly	NULL
after	NULL
stimulation	NULL
of	NULL
the	NULL
cells	NULL
by	NULL
PMA	NULL
(	NULL
Boyle	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
and	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
NFxB	NULL
be	NULL
inhibited	NULL
thereafter	NULL
by	NULL
newly	NULL
synthesized	NULL
IxB	NULL
(	NULL
Finco	NULL
and	NULL
Baldwin	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
here	NULL
clearly	NULL
show	NULL
that	NULL
both	NULL
NFB	NULL
and	NULL
API	NULL
binding	NULL
activities	NULL
remain	NULL
high	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
/ionomycin	NULL
for	NULL
4	NULL
h	NULL
,	NULL
a	NULL
time	NULL
point	NULL
at	NULL
which	NULL
we	NULL
estimated	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
was	NULL
most	NULL
active	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Gene	NULL
disruption	NULL
of	NULL
members	NULL
of	NULL
the	NULL
NFxB/Rel	NULL
family	NULL
in	NULL
mice	NULL
produces	NULL
T	NULL
cell	NULL
defects	NULL
;	NULL
disrupted	NULL
p50	NULL
results	NULL
in	NULL
T	NULL
cells	NULL
with	NULL
decreased	NULL
ability	NULL
to	NULL
proliferate	NULL
in	NULL
response	NULL
to	NULL
activation	NULL
signals	NULL
(	NULL
Sha	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
;	NULL
p65	NULL
inactivation	NULL
is	NULL
an	NULL
embryonic	NULL
lethal	NULL
mutation	NULL
,	NULL
but	NULL
does	NULL
cause	NULL
defects	NULL
in	NULL
GM-CSF	NULL
induction	NULL
in	NULL
cell	NULL
lines	NULL
(	NULL
Beg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995b	NULL
)	NULL
;	NULL
and	NULL
c-rel	NULL
disruption	NULL
results	NULL
both	NULL
in	NULL
defects	NULL
in	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
Kontgen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
and	NULL
GM-CSF	NULL
transcription	NULL
(	NULL
Gerondakis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Inactivation	NULL
of	NULL
IxB	NULL
results	NULL
in	NULL
enhanced	NULL
granulopoiesis	NULL
(	NULL
Beg	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1995a	NULL
)	NULL
,	NULL
possibly	NULL
caused	NULL
by	NULL
increased	NULL
or	NULL
constitutive	NULL
expression	NULL
of	NULL
cytokines	NULL
such	NULL
as	NULL
GM-CSF	NULL
.	NULL

Gene	NULL
disruption	NULL
of	NULL
c-jun	NULL
in	NULL
mice	NULL
appears	NULL
to	NULL
have	NULL
no	NULL
effect	NULL
upon	NULL
T	NULL
cell	NULL
proliferation	NULL
or	NULL
activation	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
but	NULL
c-fos	NULL
activation	NULL
results	NULL
in	NULL
dramatically	NULL
reduced	NULL
numbers	NULL
of	NULL
certain	NULL
T	NULL
cell	NULL
sub-sets	NULL
(	NULL
Johnson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
although	NULL
these	NULL
results	NULL
are	NULL
not	NULL
supported	NULL
by	NULL
others	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Similarly	NULL
to	NULL
ETS	NULL
!	NULL

gene	NULL
inactivation	NULL
,	NULL
these	NULL
experiments	NULL
have	NULL
accentuated	NULL
the	NULL
importance	NULL
of	NULL
NFxB	NULL
and	NULL
API	NULL
in	NULL
the	NULL
events	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
although	NULL
there	NULL
may	NULL
be	NULL
some	NULL
redundancy	NULL
in	NULL
function	NULL
between	NULL
the	NULL
different	NULL
API	NULL
family	NULL
members	NULL
.	NULL

Co-transfection	NULL
with	NULL
combinations	NULL
of	NULL
ETSI	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
resulted	NULL
in	NULL
strongly	NULL
synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
in	NULL
unstimulated	NULL
cells	NULL
.	NULL

In	NULL
all	NULL
experiments	NULL
,	NULL
transactivation	NULL
was	NULL
either	NULL
greatly	NULL
reduced	NULL
or	NULL
abolished	NULL
by	NULL
mutation	NULL
of	NULL
any	NULL
of	NULL
the	NULL
ETS	NULL
,	NULL
NFxB	NULL
or	NULL
API	NULL
binding	NULL
sites	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
ETSI1	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
transcription	NULL
factors	NULL
primarily	NULL
mediate	NULL
transactivation	NULL
through	NULL
direct	NULL
interaction	NULL
with	NULL
their	NULL
binding	NULL
sites	NULL
,	NULL
but	NULL
also	NULL
require	NULL
the	NULL
binding	NULL
of	NULL
adjacent	NULL
factors	NULL
.	NULL

Even	NULL
transactivation	NULL
by	NULL
NFxB	NULL
and	NULL
API	NULL
alone	NULL
were	NULL
also	NULL
shown	NULL
to	NULL
involve	NULL
the	NULL
ETS	NULL
binding	NULL
site	NULL
,	NULL
possibly	NULL
by	NULL
interacting	NULL
with	NULL
constitutive	NULL
ETSI	NULL
,	NULL
or	NULL
another	NULL
endogenous	NULL
ETS	NULL
family	NULL
member	NULL
.	NULL

Thus	NULL
,	NULL
a	NULL
complex	NULL
,	NULL
interdependent	NULL
,	NULL
interaction	NULL
between	NULL
ETSI1	NULL
,	NULL
NFxB	NULL
and	NULL
API	NULL
factors	NULL
appears	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
controlling	NULL
GM-CSF	NULL
transcription	NULL
.	NULL

Cooperative	NULL
synergism	NULL
between	NULL
ETSl	NULL
and	NULL
API	NULL
has	NULL
been	NULL
demonstrated	NULL
previously	NULL
with	NULL
other	NULL
promoters	NULL
(	NULL
Wasylyk	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Majerus	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
and	NULL
API	NULL
and	NULL
NFxB	NULL
are	NULL
known	NULL
to	NULL
synergise	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
shows	NULL
that	NULL
ETSl	NULL
and	NULL
NFxB	NULL
also	NULL
exhibit	NULL
transcriptional	NULL
synergy	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
these	NULL
three	NULL
factors	NULL
may	NULL
in	NULL
part	NULL
be	NULL
explained	NULL
by	NULL
findings	NULL
that	NULL
ETS	NULL
proteins	NULL
can	NULL
physically	NULL
associate	NULL
with	NULL
API	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Bassuk	NULL
and	NULL
Leiden	NULL
,	NULL
1995	NULL
)	NULL
,	NULL
a	NULL
process	NULL
required	NULL
for	NULL
transcription	NULL
involving	NULL
ETS/API1	NULL
enhancers	NULL
.	NULL

Also	NULL
,	NULL
p65	NULL
associates	NULL
with	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
(	NULL
Stein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
and	NULL
,	NULL
our	NULL
preliminary	NULL
data	NULL
suggests	NULL
,	NULL
also	NULL
with	NULL
ETS1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
these	NULL
factors	NULL
can	NULL
cooperate	NULL
and	NULL
potentially	NULL
associate	NULL
with	NULL
other	NULL
constitutive	NULL
factors	NULL
that	NULL
bind	NULL
the	NULL
proximal	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
such	NULL
as	NULL
Spl	NULL
(	NULL
Gegonne	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Perkins	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
,	NULL
CBF	NULL
(	NULL
Wotton	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
and	NULL
perhaps	NULL
YYl1	NULL
(	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Direct	NULL
promoter	NULL
association	NULL
of	NULL
ETS1l	NULL
,	NULL
NFB	NULL
,	NULL
API	NULL
and	NULL
other	NULL
factors	NULL
,	NULL
as	NULL
well	NULL
as	NULL
with	NULL
each	NULL
other	NULL
,	NULL
potentially	NULL
comprises	NULL
a	NULL
higher	NULL
order	NULL
transcriptional	NULL
complex	NULL
capable	NULL
of	NULL
mediating	NULL
high	NULL
levels	NULL
of	NULL
GM-CSF	NULL
transcription	NULL
.	NULL

We	NULL
do	NULL
not	NULL
yet	NULL
know	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
such	NULL
synergy	NULL
is	NULL
accomplished	NULL
,	NULL
but	NULL
could	NULL
involve	NULL
increased	NULL
binding	NULL
affinity	NULL
and/or	NULL
decreased	NULL
degradation	NULL
of	NULL
the	NULL
combined	NULL
factors	NULL
,	NULL
formation	NULL
of	NULL
binding	NULL
surfaces	NULL
for	NULL
additional	NULL
factors	NULL
or	NULL
components	NULL
of	NULL
the	NULL
transcriptional	NULL
machinery	NULL
,	NULL
and/or	NULL
local	NULL
conformational	NULL
changes	NULL
in	NULL
the	NULL
DNA	NULL
.	NULL

Support	NULL
for	NULL
any	NULL
of	NULL
these	NULL
models	NULL
of	NULL
cooperativity	NULL
is	NULL
preliminary	NULL
.	NULL

However	NULL
,	NULL
some	NULL
clues	NULL
exist	NULL
,	NULL
such	NULL
as	NULL
the	NULL
ability	NULL
of	NULL
p65	NULL
to	NULL
functionally	NULL
interact	NULL
with	NULL
TATA	NULL
binding	NULL
protein	NULL
and	NULL
TFIIB	NULL
,	NULL
components	NULL
of	NULL
the	NULL
basic	NULL
transcriptional	NULL
machinery	NULL
(	NULL
Schmitz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
and	NULL
the	NULL
proposed	NULL
abilities	NULL
of	NULL
NFxB	NULL
and	NULL
API	NULL
to	NULL
induce	NULL
bending	NULL
of	NULL
DNA	NULL
upon	NULL
binding	NULL
(	NULL
Kerppola	NULL
and	NULL
Curran	NULL
,	NULL
1991	NULL
;	NULL
Pazin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

It	NULL
seems	NULL
likely	NULL
that	NULL
further	NULL
study	NULL
of	NULL
the	NULL
GM	NULL
CSF	NULL
promoter	NULL
will	NULL
describe	NULL
a	NULL
very	NULL
complex	NULL
set	NULL
of	NULL
interactive	NULL
transcriptional	NULL
control	NULL
mechanisms	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Cell	NULL
lines	NULL
and	NULL
culture	NULL
Jurkat	NULL
cells	NULL
,	NULL
a	NULL
human	NULL
leukemic	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
and	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
.	NULL

Monkey	NULL
COS7	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
DMEM	NULL
supplemented	NULL
with	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
penicillin	NULL
and	NULL
streptomycin	NULL
as	NULL
above	NULL
.	NULL

Both	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
a	NULL
humidified	NULL
incubator	NULL
at	NULL
37Â°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

Plasmid	NULL
constructs	NULL
for	NULL
transfection	NULL
pGM600	NULL
contains	NULL
approximately	NULL
600	NULL
bp	NULL
of	NULL
sequence	NULL
preceding	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
human	NULL
GM-CSF	NULL
promoter	NULL
.	NULL

An	NULL
EcoRI-HindlII	NULL
fragment	NULL
from	NULL
pHGMO.6	NULL
(	NULL
Cockerill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
containing	NULL
the	NULL
promoter	NULL
was	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
in	NULL
pCAT-BASIC	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

pGM600-ETSm1	NULL
,	NULL
pGM600-xBm1l	NULL
and	NULL
pGM600-AP1m1	NULL
contain	NULL
mutations	NULL
in	NULL
the	NULL
ETS	NULL
,	NULL
NFxB	NULL
and	NULL
AP1	NULL
binding	NULL
sites	NULL
analogous	NULL
to	NULL
those	NULL
found	NULL
in	NULL
the	NULL
oligonucleotides	NULL
ETSm1	NULL
,	NULL
xBm1l	NULL
and	NULL
APIlm1	NULL
,	NULL
respectively	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
were	NULL
produced	NULL
by	NULL
PCR	NULL
of	NULL
pGM600	NULL
using	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
respective	NULL
mutations	NULL
.	NULL

The	NULL
resulting	NULL
PCR	NULL
products	NULL
were	NULL
substituted	NULL
back	NULL
into	NULL
pGM600	NULL
.	NULL

The	NULL
ETS1	NULL
,	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
expression	NULL
constructs	NULL
are	NULL
based	NULL
on	NULL
the	NULL
pEFBOS	NULL
expression	NULL
vector	NULL
(	NULL
Mizushima	NULL
and	NULL
Nagata	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
human	NULL
etsl	NULL
cDNA	NULL
from	NULL
pGEMT7HE-1	NULL
(	NULL
Watson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
was	NULL
subcloned	NULL
as	NULL
a	NULL
blunt	NULL
KpnlI-HindlII	NULL
fragment	NULL
into	NULL
the	NULL
blunt-ended	NULL
Xbel	NULL
cloning	NULL
site	NULL
of	NULL
pEFBOS	NULL
.	NULL

Human	NULL
c-fos	NULL
and	NULL
mouse	NULL
c-jun	NULL
cDNAs	NULL
(	NULL
gifts	NULL
of	NULL
Jane	NULL
Visvader	NULL
,	NULL
Walter	NULL
and	NULL
Eliza	NULL
Hall	NULL
Institute	NULL
of	NULL
Medical	NULL
Research	NULL
)	NULL
were	NULL
blunt	NULL
cloned	NULL
into	NULL
pEFBOS	NULL
.	NULL

p50	NULL
(	NULL
Apal	NULL
insert	NULL
)	NULL
and	NULL
p65	NULL
(	NULL
Nof	NULL
insert	NULL
)	NULL
NFxB	NULL
subunit	NULL
cDNAs	NULL
were	NULL
ligated	NULL
into	NULL
the	NULL
pRC/	NULL
CMV	NULL
(	NULL
Invitrogen	NULL
)	NULL
expression	NULL
vector	NULL
(	NULL
Dunn	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

The	NULL
integrity	NULL
of	NULL
all	NULL
constructs	NULL
was	NULL
confirmed	NULL
by	NULL
sequence	NULL
analysis	NULL
.	NULL

Transfection	NULL
of	NULL
Jurkat	NULL
cells	NULL
and	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
assays	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
and	NULL
6	NULL
ug	NULL
of	NULL
expression	NULL
constructs	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
growth	NULL
media	NULL
24	NULL
h	NULL
following	NULL
transfection	NULL
,	NULL
where	NULL
appropriate	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
a	NULL
further	NULL
24	NULL
h	NULL
later	NULL
and	NULL
processed	NULL
for	NULL
CAT	NULL
Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
assays	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

The	NULL
raw	NULL
CAT	NULL
data	NULL
for	NULL
each	NULL
construct	NULL
(	NULL
pGM600	NULL
,	NULL
pGM600-ETSm1	NULL
,	NULL
pGM600-	NULL
Â«	NULL
xBm1l	NULL
,	NULL
pGM600-APlm1l	NULL
)	NULL
,	NULL
with	NULL
the	NULL
various	NULL
treatment/co-transfections	NULL
,	NULL
was	NULL
normalised	NULL
to	NULL
its	NULL
own	NULL
basal	NULL
expression	NULL
,	NULL
which	NULL
was	NULL
given	NULL
the	NULL
value	NULL
of	NULL
'one	NULL
'	NULL
.	NULL

The	NULL
mean	NULL
,	NULL
and	NULL
standard	NULL
error	NULL
of	NULL
the	NULL
mean	NULL
(	NULL
s.e.m	NULL
.	NULL
)	NULL

,	NULL
of	NULL
at	NULL
least	NULL
four	NULL
replicates	NULL
for	NULL
each	NULL
experiment	NULL
was	NULL
graphed	NULL
to	NULL
show	NULL
a	NULL
'fold	NULL
induction	NULL
'	NULL
over	NULL
basal	NULL
expression	NULL
,	NULL
to	NULL
facilitate	NULL
comparison	NULL
between	NULL
the	NULL
different	NULL
mutations	NULL
and	NULL
treatments/co-transfections	NULL
.	NULL

Data	NULL
were	NULL
subjected	NULL
to	NULL
statistical	NULL
analysis	NULL
using	NULL
unpaired	NULL
f-tests	NULL
,	NULL
with	NULL
resultant	NULL
P	NULL
values	NULL
less	NULL
than	NULL
0.05	NULL
considered	NULL
significant	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSA	NULL
)	NULL
Recombinant	NULL
p50	NULL
,	NULL
c-Fos	NULL
and	NULL
c-Jun	NULL
were	NULL
produced	NULL
by	NULL
transient	NULL
transfection	NULL
of	NULL
the	NULL
respective	NULL
expression	NULL
vectors	NULL
into	NULL
COS	NULL
cells	NULL
Sub-confluent	NULL
cells	NULL
were	NULL
trypsinized	NULL
,	NULL
washed	NULL
in	NULL
growth	NULL
medium	NULL
(	NULL
as	NULL
above	NULL
)	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
PBS	NULL
with	NULL
20	NULL
mm	NULL
HEPES	NULL
at	NULL
5x	NULL
cells/ml	NULL
.	NULL

Three-hundred	NULL
ul	NULL
of	NULL
cells	NULL
were	NULL
mixed	NULL
with	NULL
20	NULL
ug	NULL
DNA	NULL
in	NULL
0.4	NULL
cm	NULL
gap	NULL
electroporation	NULL
cuvettes	NULL
and	NULL
pulsed	NULL
at	NULL
170	NULL
V	NULL
and	NULL
500	NULL
uF	NULL
(	NULL
Biorad	NULL
Gene	NULL
Pulsar	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
replated	NULL
into	NULL
10	NULL
cm	NULL
petri	NULL
dishes	NULL
and	NULL
harvested	NULL
24	NULL
h	NULL
later	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
grown	NULL
to	NULL
5x	NULL
10Â°	NULL
cells/ml	NULL
and	NULL
were	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
for	NULL
4	NULL
h	NULL
prior	NULL
to	NULL
harvest	NULL
.	NULL

Nuclear	NULL
lysates	NULL
from	NULL
COS	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
experiments	NULL
with	NULL
nuclear	NULL
lysates	NULL
were	NULL
performed	NULL
using	NULL
EMSA	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Thomas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
purified	NULL
double	NULL
stranded	NULL
oligonucleotides	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
Â«	NULL
-	NULL
``	NULL
P	NULL
]	NULL
dATP	NULL
by	NULL
Klenow	NULL
fill-in	NULL
reaction	NULL
.	NULL

One	NULL
ng	NULL
oligonucleotide	NULL
probe	NULL
was	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
with	NULL
2	NULL
ug	NULL
protein	NULL
in	NULL
DNA	NULL
binding	NULL
buffer	NULL
(	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
10	NULL
mm	NULL
Tris.Cl	NULL
pH	NULL
8.0	NULL
,	NULL
50	NULL
mm	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
5	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
1	NULL
mg/ml	NULL
BSA	NULL
,	NULL
500	NULL
ng/ml	NULL
-	NULL
poly-d	NULL
(	NULL
I-C	NULL
)	NULL
.d	NULL
(	NULL
I-C	NULL
)	NULL
,	NULL
-	NULL
500	NULL
ng/ml	NULL
-	NULL
poly-dI.dC	NULL
,	NULL
200	NULL
ng/ml	NULL
sheared	NULL
salmon	NULL
sperm	NULL
DNA	NULL
)	NULL
,	NULL
+100	NULL
ng	NULL
unlabeled	NULL
competitor	NULL
oligonucleotides	NULL
,	NULL
+antibodies	NULL
,	NULL
in	NULL
10	NULL
ul	NULL
final	NULL
volume	NULL
.	NULL

Assays	NULL
were	NULL
run	NULL
through	NULL
non-denaturing	NULL
,	NULL
7	NULL
%	NULL
acrylamide	NULL
(	NULL
29	NULL
acrylamide:1	NULL
bis-acrylamide	NULL
)	NULL
,	NULL
0.5	NULL
x	NULL
TBE	NULL
gels	NULL
,	NULL
until	NULL
free	NULL
oligonucleotides	NULL
had	NULL
run	NULL
off	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
gel	NULL
,	NULL
to	NULL
maximise	NULL
separation	NULL
of	NULL
complexes	NULL
.	NULL

Oligonucleotide	NULL
sequences	NULL
(	NULL
shown	NULL
in	NULL
double	NULL
stranded	NULL
conformation	NULL
)	NULL
GMETS	NULL
gatcCACAGAGGAAATGATT	NULL
GTGTCTCCTTTACTAActaqg	NULL
GMETSml	NULL
gatcCACAGAAGAAATGATT	NULL
GTGTCTTCTTTACTAActaqg	NULL
MSV	NULL
gatcGAGAGCGGAAGCGCGC	NULL
CTCTCGCCTTCGCGCGctag	NULL
GMKB	NULL
gatcTCAGGTAGTTCCCCCG	NULL
AGTCCATCAAGGGGGCctag	NULL
GMxBm1	NULL
gatcTCAGGTAGTTTTCCCG	NULL
AGTCCATCAAAAGGGCctag	NULL
NFxkBcons	NULL
gatcTTGAGGGGACTTTCCC	NULL
AACTCCCCTGAAAGGGctaqg	NULL
gatcCACCATTAATCATTTC	NULL
GTGGTAATTAGTAAAGctaq	NULL
GMAPIm1l	NULL
gatcCACCAGATAGCATTTC	NULL
GTGGTCTATCGTAAAGctaq	NULL
APlcons	NULL
gatcCTTGATGAGTCAGCCG	NULL
GAACTACTCAGTCGGCctaq	NULL
GMAPL	NULL
Antibodies	NULL
for	NULL
EMSA	NULL
analysis	NULL
ETS	NULL
antibody	NULL
;	NULL
Â«	NULL
Ets1	NULL
-	NULL
monoclonal	NULL
E44	NULL
.	NULL

NFxB	NULL
antibodies	NULL
;	NULL
Â«	NULL
IxB	NULL
-	NULL
polyclonal	NULL
KD21/1	NULL
(	NULL
gift	NULL
of	NULL
Steve	NULL
Gerondakis	NULL
,	NULL
Walter	NULL
and	NULL
Eliza	NULL
Hall	NULL
Institute	NULL
of	NULL
Medical	NULL
Research	NULL
)	NULL
,	NULL
Â«	NULL
Rel	NULL
-	NULL
monoclonal	NULL
Â«	NULL
497	NULL
,	NULL
Â«	NULL
p50	NULL
-	NULL
monoclonal	NULL
SC114	NULL
(	NULL
Santa	NULL
2853	NULL
Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
2854	NULL
Cruz	NULL
)	NULL
,	NULL
and	NULL
Â«	NULL
p65	NULL
-	NULL
monoclonal	NULL
SC109	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
.	NULL

API	NULL
antibodies	NULL
;	NULL
Â«	NULL
PFos	NULL
-	NULL
polyclonal	NULL
'M	NULL
'	NULL
(	NULL
pan-Fos	NULL
cross-reacts	NULL
with	NULL
Fos	NULL
family	NULL
members	NULL
)	NULL
,	NULL
Â«	NULL
PJun	NULL
-	NULL
polyclonal	NULL
(	NULL
pan-Jun	NULL
cross-reacts	NULL
with	NULL
Jun	NULL
family	NULL
members	NULL
)	NULL
(	NULL
gifts	NULL
of	NULL
Donna	NULL
R	NULL
Cohen	NULL
,	NULL
Australian	NULL
National	NULL
University	NULL
)	NULL
,	NULL
Â«	NULL
cFos	NULL
-	NULL
c-Fos	NULL
polyclonal	NULL
SCS2	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
,	NULL
and	NULL
acJun	NULL
-	NULL
c-Jun	NULL
polyclonal	NULL
SC45	NULL
(	NULL
Santa	NULL
Cruz	NULL
)	NULL
.	NULL

References	NULL
Arai	NULL
K	NULL
,	NULL
Lee	NULL
F	NULL
,	NULL
Miyajima	NULL
A	NULL
,	NULL
Miyatake	NULL
S	NULL
,	NULL
Arai	NULL
N	NULL
and	NULL
Yakota	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
59	NULL
,	NULL
783-836	NULL
.	NULL

Bassuk	NULL
AG	NULL
and	NULL
Leiden	NULL
JM	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Immunity	NULL
,	NULL
3	NULL
,	NULL
223-237	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Ruben	NULL
SM	NULL
,	NULL
Scheinman	NULL
RJ	NULL
,	NULL
Haskill	NULL
S	NULL
,	NULL
Rosen	NULL
CA	NULL
and	NULL
Baldwin	NULL
Jr.	NULL
AS	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
6	NULL
,	NULL
1899-1913	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Sha	NULL
WC	NULL
,	NULL
Bronson	NULL
RT	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
19952	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
,	NULL
2736-2746	NULL
.	NULL

Beg	NULL
AA	NULL
,	NULL
Sha	NULL
WC	NULL
,	NULL
Bronson	NULL
RT	NULL
,	NULL
Ghosh	NULL
S	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
1995b	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
376	NULL
,	NULL
167-170	NULL
.	NULL

Bhat	NULL
NK	NULL
,	NULL
Thompson	NULL
CB	NULL
,	NULL
Lindsten	NULL
T	NULL
,	NULL
June	NULL
CH	NULL
,	NULL
Fujiwara	NULL
S	NULL
Koizumi	NULL
S	NULL
,	NULL
Fisher	NULL
RJ	NULL
and	NULL
Papas	NULL
TS	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
,	NULL
3723-3727	NULL
.	NULL

Boise	NULL
LH	NULL
,	NULL
Petryniak	NULL
B	NULL
,	NULL
Mao	NULL
X	NULL
,	NULL
June	NULL
CH	NULL
,	NULL
Wang	NULL
CY	NULL
,	NULL
Lindsten	NULL
T	NULL
,	NULL
Bravo	NULL
R	NULL
,	NULL
Kovary	NULL
K	NULL
,	NULL
Leiden	NULL
JM	NULL
and	NULL
Thompson	NULL
CB	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
13	NULL
,	NULL
1911-1919	NULL
.	NULL

Boyle	NULL
WJ	NULL
,	NULL
Smeal	NULL
T	NULL
,	NULL
Defize	NULL
LH	NULL
,	NULL
Angel	NULL
P	NULL
,	NULL
Woodgett	NULL
JR	NULL
,	NULL
Karin	NULL
M	NULL
and	NULL
Hunter	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
64	NULL
,	NULL
573-584	NULL
.	NULL

Bradford	NULL
AP	NULL
,	NULL
Conrad	NULL
KE	NULL
,	NULL
Wasylyk	NULL
C	NULL
,	NULL
Wasylyk	NULL
B	NULL
and	NULL
Gutierrez-Hartmann	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
2849-2857	NULL
.	NULL

Brorson	NULL
KA	NULL
,	NULL
Beverly	NULL
B	NULL
,	NULL
Kang	NULL
S	NULL
,	NULL
Lenardo	NULL
M	NULL
and	NULL
Schwartz	NULL
RH	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
147	NULL
,	NULL
3601-3609	NULL
.	NULL

Chen	NULL
J	NULL
,	NULL
Stewart	NULL
V	NULL
,	NULL
Spyrou	NULL
G	NULL
,	NULL
Hilberg	NULL
F	NULL
,	NULL
Wagner	NULL
EF	NULL
and	NULL
Alt	NULL
FW	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Immunity	NULL
,	NULL
1	NULL
,	NULL
65-72	NULL
.	NULL

Cockerill	NULL
PN	NULL
,	NULL
Shannon	NULL
MF	NULL
,	NULL
Bert	NULL
AG	NULL
,	NULL
Ryan	NULL
GR	NULL
and	NULL
Vadas	NULL
MA	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
2466-2470	NULL
.	NULL

Cockerill	NULL
PN	NULL
,	NULL
Bert	NULL
AG	NULL
,	NULL
Jenkins	NULL
F	NULL
,	NULL
Ryan	NULL
GR	NULL
,	NULL
Shannon	NULL
MF	NULL
and	NULL
Vadas	NULL
MA	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
15	NULL
,	NULL
2071-2079	NULL
.	NULL

Cockerill	NULL
PN	NULL
,	NULL
Osborne	NULL
CS	NULL
,	NULL
Bert	NULL
AG	NULL
and	NULL
Grotto	NULL
RJM	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

,	NULL
7	NULL
,	NULL
917-922	NULL
.	NULL

Cogswell	NULL
PC	NULL
,	NULL
Scheinman	NULL
RI	NULL
and	NULL
Baldwin	NULL
Jr	NULL
AS	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
150	NULL
,	NULL
2794-2804	NULL
.	NULL

Curran	NULL
T	NULL
and	NULL
Franza	NULL
Jr	NULL
BR	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
55	NULL
,	NULL
395-397	NULL
.	NULL

Deng	NULL
T	NULL
and	NULL
Karin	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
,	NULL
479-490	NULL
.	NULL

Dunn	NULL
SM	NULL
,	NULL
Coles	NULL
LS	NULL
,	NULL
Lang	NULL
RK	NULL
,	NULL
Gerondakis	NULL
S	NULL
,	NULL
Vadas	NULL
MA	NULL
and	NULL
Shannon	NULL
MF	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
83	NULL
,	NULL
2469-2479	NULL
.	NULL

Finco	NULL
TS	NULL
and	NULL
Baldwin	NULL
AS	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Immunity	NULL
,	NULL
3	NULL
,	NULL
263-272	NULL
.	NULL

Fisher	NULL
CI	NULL
,	NULL
Ghysdael	NULL
J	NULL
and	NULL
Cambier	NULL
JC	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
146	NULL
,	NULL
1743-1749	NULL
.	NULL

Gegonne	NULL
A	NULL
,	NULL
Bosselut	NULL
R	NULL
,	NULL
Bailly	NULL
R	NULL
and	NULL
Ghysdael	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
1169-1178	NULL
.	NULL

Gerondakis	NULL
S	NULL
,	NULL
Strasser	NULL
A	NULL
,	NULL
Metcalf	NULL
D	NULL
,	NULL
Grigoriadis	NULL
G	NULL
,	NULL
Scheerlinck	NULL
JY	NULL
and	NULL
Grumont	NULL
RJ	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
93	NULL
,	NULL
3405-3409	NULL
.	NULL

Himes	NULL
SR	NULL
,	NULL
Katsikeros	NULL
R	NULL
and	NULL
Shannon	NULL
MF	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Viro/	NULL
.	NULL

,	NULL
70	NULL
,	NULL
4001-4008	NULL
.	NULL

Israel	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Trends	NULL
Genet	NULL
.	NULL

,	NULL
11	NULL
,	NULL
203-205	NULL
.	NULL

Iwai	NULL
Y	NULL
,	NULL
Akahane	NULL
K	NULL
,	NULL
Pluznik	NULL
DH	NULL
and	NULL
Cohen	NULL
RB	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
150	NULL
,	NULL
4386-4394	NULL
.	NULL

Jain	NULL
J	NULL
,	NULL
Nalefski	NULL
EA	NULL
,	NULL
McCaffrey	NULL
PG	NULL
,	NULL
Johnson	NULL
RS	NULL
,	NULL
Spiegelman	NULL
BM	NULL
,	NULL
Papaioannou	NULL
V	NULL
and	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
1566-1574	NULL
.	NULL

Janknecht	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Immunobiology	NULL
,	NULL
193	NULL
,	NULL
137-142	NULL
.	NULL

Johnson	NULL
RS	NULL
,	NULL
Spiegelman	NULL
BM	NULL
and	NULL
Papaioannou	NULL
V.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
71	NULL
,	NULL
577-586	NULL
.	NULL

Karin	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
270	NULL
,	NULL
16483-16486	NULL
.	NULL

Kerppola	NULL
T	NULL
and	NULL
Curran	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
373	NULL
,	NULL
199-200	NULL
.	NULL

Kerppola	NULL
TK	NULL
and	NULL
Curran	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
66	NULL
,	NULL
317-326	NULL
.	NULL

Klausner	NULL
RD	NULL
and	NULL
Samelson	NULL
LE	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
64	NULL
,	NULL
875-878	NULL
.	NULL

Koizumi	NULL
S	NULL
,	NULL
Fisher	NULL
RJ	NULL
,	NULL
Fujiwara	NULL
S	NULL
,	NULL
Jorcyk	NULL
C	NULL
,	NULL
Bhat	NULL
NK	NULL
,	NULL
Seth	NULL
A	NULL
and	NULL
Papas	NULL
TS	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
5	NULL
,	NULL
675-681	NULL
.	NULL

Acknowledgements	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
National	NULL
Health	NULL
and	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Australia	NULL
and	NULL
the	NULL
Victorian	NULL
Health	NULL
Promotion	NULL
Foundation	NULL
.	NULL

Kontgen	NULL
F	NULL
,	NULL
Grumont	NULL
RJ	NULL
,	NULL
Strasser	NULL
A	NULL
,	NULL
Metcalf	NULL
D	NULL
,	NULL
Li	NULL
R	NULL
,	NULL
Tarlinton	NULL
D	NULL
and	NULL
Gerondakis	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
,	NULL
1965-1977	NULL
.	NULL

Koyano-Nakagawa	NULL
N	NULL
,	NULL
Nishida	NULL
J	NULL
,	NULL
Arai	NULL
N	NULL
,	NULL
Arai	NULL
K	NULL
and	NULL
Yokota	NULL
T.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
5	NULL
,	NULL
345-352	NULL
.	NULL

Li	NULL
CC	NULL
,	NULL
Dai	NULL
RM	NULL
,	NULL
Chen	NULL
E	NULL
and	NULL
Longo	NULL
DL	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

J.	NULL
Bio	NULL
!	NULL

.	NULL

Chem	NULL
.	NULL

,	NULL
269	NULL
,	NULL
30089-30092	NULL
.	NULL

Li	NULL
CC	NULL
,	NULL
Dai	NULL
RM	NULL
and	NULL
Longo	NULL
DL	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
215	NULL
,	NULL
292-301	NULL
.	NULL

Logan	NULL
SK	NULL
,	NULL
Garabedian	NULL
MJ	NULL
,	NULL
Campbell	NULL
CE	NULL
and	NULL
Werb	NULL
Z	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
271	NULL
,	NULL
774-782	NULL
.	NULL

Majerus	NULL
MA	NULL
,	NULL
Bibollet-Ruche	NULL
F	NULL
,	NULL
Telliez	NULL
JB	NULL
,	NULL
Wasylyk	NULL
B	NULL
and	NULL
Bailleul	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
20	NULL
,	NULL
2699-2703	NULL
.	NULL

Makover	NULL
D	NULL
,	NULL
Cuddy	NULL
M	NULL
,	NULL
Yum	NULL
S	NULL
,	NULL
Bradley	NULL
K	NULL
,	NULL
Alpers	NULL
J	NULL
,	NULL
Sukhatme	NULL
V	NULL
and	NULL
Reed	NULL
JC	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
6	NULL
,	NULL
455-460	NULL
.	NULL

Masuda	NULL
ES	NULL
,	NULL
Tokumitsu	NULL
H	NULL
,	NULL
Tsuboi	NULL
A	NULL
,	NULL
Shlomai	NULL
J	NULL
,	NULL
Hung	NULL
P	NULL
,	NULL
Arai	NULL
K	NULL
and	NULL
Arai	NULL
N.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
13	NULL
,	NULL
7399-7407	NULL
.	NULL

Masuda	NULL
ES	NULL
,	NULL
Yamaguchi-Iwai	NULL
Y	NULL
,	NULL
Tsuboi	NULL
A	NULL
,	NULL
Hung	NULL
P	NULL
,	NULL
Arai	NULL
K	NULL
and	NULL
Arai	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
205	NULL
,	NULL
1518-1525	NULL
.	NULL

Meyer	NULL
R	NULL
,	NULL
Hatada	NULL
EN	NULL
,	NULL
Hohmann	NULL
HP	NULL
,	NULL
Haiker	NULL
M	NULL
,	NULL
Bartsch	NULL
C	NULL
,	NULL
Rothlisberger	NULL
U	NULL
,	NULL
Lahm	NULL
HW	NULL
,	NULL
Schlaeger	NULL
EJ	NULL
,	NULL
van	NULL
Loon	NULL
AP	NULL
and	NULL
Scheidereit	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
,	NULL
966-970	NULL
.	NULL

Miyajima	NULL
A	NULL
,	NULL
Miyatake	NULL
S	NULL
,	NULL
Schreurs	NULL
J	NULL
,	NULL
De	NULL
Vries	NULL
J	NULL
,	NULL
Arai	NULL
N	NULL
,	NULL
Yokota	NULL
T	NULL
and	NULL
Arai	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
.	NULL

FASEB	NULL
J.	NULL
,	NULL
2	NULL
,	NULL
2462-2473	NULL
.	NULL

Mizushima	NULL
S	NULL
and	NULL
Nagata	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Nuc	NULL
.	NULL

Acids	NULL
Res	NULL
.	NULL

,	NULL
18	NULL
,	NULL
5322	NULL
.	NULL

Muthusamy	NULL
N	NULL
,	NULL
Barton	NULL
K	NULL
and	NULL
Leiden	NULL
JM	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
377	NULL
,	NULL
639-642	NULL
.	NULL

Nimer	NULL
SD	NULL
,	NULL
Fraser	NULL
J	NULL
,	NULL
Richards	NULL
J	NULL
,	NULL
Lynch	NULL
M	NULL
and	NULL
Gasson	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
6084-6088	NULL
.	NULL

Nimer	NULL
SD	NULL
,	NULL
Zhang	NULL
W	NULL
,	NULL
Kwan	NULL
K	NULL
,	NULL
Wang	NULL
Y	NULL
and	NULL
Zhang	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
87	NULL
,	NULL
3694-3703	NULL
.	NULL

Osborne	NULL
CS	NULL
,	NULL
Vadas	NULL
MA	NULL
and	NULL
Cockerill	NULL
PN	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
155	NULL
,	NULL
226-235	NULL
.	NULL

Pazin	NULL
MJ	NULL
,	NULL
Sheridan	NULL
PL	NULL
,	NULL
Cannon	NULL
K	NULL
,	NULL
Cao	NULL
Z	NULL
,	NULL
Keck	NULL
JG	NULL
,	NULL
Kadonaga	NULL
JT	NULL
and	NULL
Jones	NULL
KA	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
10	NULL
,	NULL
37-49	NULL
.	NULL

Perkins	NULL
ND	NULL
,	NULL
Agranoff	NULL
AB	NULL
,	NULL
Pascal	NULL
E	NULL
and	NULL
Nabel	NULL
GJ	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
6570-6583	NULL
.	NULL

Rabault	NULL
B	NULL
and	NULL
Ghysdael	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
269	NULL
,	NULL
28143-28151	NULL
.	NULL

Radler-Pohl	NULL
A	NULL
,	NULL
Gebel	NULL
S	NULL
,	NULL
Sachsenmaier	NULL
C	NULL
,	NULL
Konig	NULL
H	NULL
,	NULL
Kramer	NULL
M	NULL
,	NULL
Oehler	NULL
T	NULL
,	NULL
Streile	NULL
M	NULL
,	NULL
Ponta	NULL
H	NULL
,	NULL
Rapp	NULL
U	NULL
,	NULL
Rahmsdorf	NULL
HJ	NULL
and	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Ann	NULL
.	NULL

N.Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
684	NULL
,	NULL
127-148	NULL
.	NULL

Rincon	NULL
M	NULL
and	NULL
Flavell	NULL
RA	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
4370-4381	NULL
.	NULL

Romano-Spica	NULL
V	NULL
,	NULL
Georgiou	NULL
P	NULL
,	NULL
Suzuki	NULL
H	NULL
,	NULL
Papas	NULL
TS	NULL
and	NULL
Bhat	NULL
NK	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
154	NULL
,	NULL
2724-2732	NULL
.	NULL

Schmitz	NULL
ML	NULL
,	NULL
Stelzer	NULL
G	NULL
,	NULL
Altmann	NULL
H	NULL
,	NULL
Meisterernst	NULL
M	NULL
and	NULL
Bacuerle	NULL
PA.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
270	NULL
,	NULL
7219-7226	NULL
.	NULL

Schmitz	NULL
ML	NULL
and	NULL
Baeuerle	NULL
PA.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
10	NULL
,	NULL
3805	NULL
3817	NULL
.	NULL

Sha	NULL
WC	NULL
,	NULL
Liou	NULL
HC	NULL
,	NULL
Toumanen	NULL
EI	NULL
and	NULL
Baltimore	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
80	NULL
,	NULL
321-330	NULL
.	NULL

Shannon	NULL
MF	NULL
,	NULL
Himes	NULL
SR	NULL
and	NULL
Coles	NULL
LS	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

J.	NULL
Leukoc	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
57	NULL
,	NULL
767-773	NULL
.	NULL

Shaw	NULL
G	NULL
and	NULL
Kamen	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
46	NULL
,	NULL
659-667	NULL
.	NULL

Stanley	NULL
E	NULL
,	NULL
Metcalf	NULL
D	NULL
,	NULL
Sobieszcezuk	NULL
P	NULL
,	NULL
Gough	NULL
NM	NULL
and	NULL
Dunn	NULL
AR	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
4	NULL
,	NULL
2569-2573	NULL
.	NULL

Stein	NULL
B	NULL
,	NULL
Baldwin	NULL
Jr	NULL
AS	NULL
,	NULL
Ballard	NULL
DW	NULL
,	NULL
Greene	NULL
WC	NULL
,	NULL
Angel	NULL
P	NULL
and	NULL
Herrlich	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
3879-3891	NULL
.	NULL

Sugimoto	NULL
K	NULL
,	NULL
Tsuboi	NULL
A	NULL
,	NULL
Miyatake	NULL
S	NULL
,	NULL
Arai	NULL
K	NULL
and	NULL
Arai	NULL
N.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
2	NULL
,	NULL
787-794	NULL
.	NULL

Takahashi	NULL
A	NULL
,	NULL
Satake	NULL
M	NULL
,	NULL
Yamaguchi-Iwai	NULL
Y	NULL
,	NULL
Bae	NULL
SC	NULL
,	NULL
Lu	NULL
J	NULL
,	NULL
Maruyama	NULL
M	NULL
,	NULL
Zhang	NULL
YW	NULL
,	NULL
Oka	NULL
H	NULL
,	NULL
Arai	NULL
N	NULL
,	NULL
Arai	NULL
K	NULL
and	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Blood	NULL
,	NULL
86	NULL
,	NULL
607-616	NULL
.	NULL

Thomas	NULL
RS	NULL
,	NULL
Tymms	NULL
MJ	NULL
,	NULL
Seth	NULL
A	NULL
,	NULL
Shannon	NULL
MF	NULL
and	NULL
Kola	NULL
I	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
.	NULL

Oncogene	NULL
,	NULL
11	NULL
,	NULL
2135-2143	NULL
.	NULL

Tsuboi	NULL
A	NULL
,	NULL
Muramatsu	NULL
M	NULL
,	NULL
Tsutsumi	NULL
A	NULL
,	NULL
Arai	NULL
K	NULL
and	NULL
Arai	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

,	NULL
199	NULL
,	NULL
1064-1072	NULL
.	NULL

Valge	NULL
VE	NULL
,	NULL
Wong	NULL
JG	NULL
,	NULL
Datliof	NULL
BM	NULL
,	NULL
Sinskey	NULL
AJ	NULL
and	NULL
Rao	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Cell	NULL
,	NULL
55	NULL
,	NULL
101-112	NULL
.	NULL

Verma	NULL
IM	NULL
,	NULL
Stevenson	NULL
JK	NULL
,	NULL
Schwarz	NULL
EM	NULL
,	NULL
Van	NULL
Antwerp	NULL
D	NULL
and	NULL
Miyamoto	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
,	NULL
2723-2735	NULL
.	NULL

Wang	NULL
CY	NULL
,	NULL
Bassuk	NULL
AG	NULL
,	NULL
Boise	NULL
LH	NULL
,	NULL
Thompson	NULL
CB	NULL
,	NULL
Bravo	NULL
R	NULL
and	NULL
Leiden	NULL
JM	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
1153-1159	NULL
.	NULL

Wang	NULL
ZQ	NULL
,	NULL
Ovitt	NULL
C	NULL
,	NULL
Grigoriadis	NULL
AE	NULL
,	NULL
Mohle-Steinlein	NULL
U	NULL
,	NULL
Ruther	NULL
U	NULL
and	NULL
Wagner	NULL
EF	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
360	NULL
,	NULL
741-745	NULL
.	NULL

Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
RS	NULL
Thomas	NULL
et	NULL
al	NULL
Wasylyk	NULL
B	NULL
,	NULL
Wasylyk	NULL
C	NULL
,	NULL
Flores	NULL
P	NULL
,	NULL
Begue	NULL
A	NULL
,	NULL
Leprince	NULL
D	NULL
and	NULL
Stehelin	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Nature	NULL
,	NULL
346	NULL
,	NULL
191-193	NULL
.	NULL

Watson	NULL
DK	NULL
,	NULL
McWilliams	NULL
MJ	NULL
,	NULL
Lapis	NULL
P	NULL
,	NULL
Lautenberger	NULL
JA	NULL
,	NULL
Schweinfest	NULL
CW	NULL
and	NULL
Papas	NULL
TS	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
7862-7866	NULL
.	NULL

Woodgett	NULL
JR	NULL
,	NULL
Pulverer	NULL
BJ	NULL
,	NULL
Nikolakaki	NULL
E	NULL
,	NULL
Plyte	NULL
S	NULL
,	NULL
Hughes	NULL
K	NULL
,	NULL
Franklin	NULL
CC	NULL
and	NULL
Kraft	NULL
AS	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Adv	NULL
.	NULL

Second	NULL
Messenger	NULL
Phosphoprotein	NULL
Res	NULL
.	NULL

,	NULL
28	NULL
,	NULL
261-269	NULL
.	NULL

Wotton	NULL
D	NULL
,	NULL
Ghysdael	NULL
J	NULL
,	NULL
Wang	NULL
S	NULL
,	NULL
Speck	NULL
NA	NULL
and	NULL
Owen	NULL
MJ	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
840-850	NULL
.	NULL

Yang	NULL
BS	NULL
,	NULL
Hauser	NULL
CA	NULL
,	NULL
Henkel	NULL
G	NULL
,	NULL
Colman	NULL
MS	NULL
,	NULL
Van	NULL
Beveren	NULL
C	NULL
,	NULL
Stacey	NULL
KJ	NULL
,	NULL
Hume	NULL
DA	NULL
,	NULL
Maki	NULL
RA	NULL
and	NULL
Ostrowski	NULL
MC	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
,	NULL
538-547	NULL
.	NULL

Ye	NULL
J	NULL
,	NULL
Young	NULL
HA	NULL
,	NULL
Ortaldo	NULL
JR	NULL
and	NULL
Ghosh	NULL
P.	NULL
(	NULL
1994	NULL
)	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
22	NULL
,	NULL
5672-5678	NULL
.	NULL

Ye	NULL
J	NULL
,	NULL
Zhang	NULL
X	NULL
and	NULL
Dong	NULL
Z	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
,	NULL
157	NULL
167	NULL
.	NULL

2855	NULL

